MYNZ Mainz BioMed NV

Exhibit 99.1

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes to those statements included in Exhibit 99.2 to this Form 6-K. This discussion and analysis contains forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled “Risk Factors” and elsewhere in our Annual Report for the Year ended December 31, 2023 on Form 20-F, filed with the U.S. Securities and Exchange Commission on April 9, 2024. You should carefully read the “Risk Factors” to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements.

 

Organization and Overview of Operations

 

We develop and sell in-vitro diagnostic (“IVD”) tests for the early detection of cancer. Our flagship ColoAlert product is being marketed and sold in European markets. We are currently developing our next generation colorectal cancer screening product and intend to launch that product in the future in the United States and in Europe. We additionally operate a clinical diagnostic laboratory and distribute our IVD kits to third-party laboratories in Europe and through our on-line store in Germany. In addition, we conduct research and development to increase and diversify our product portfolio. During 2023, we also performed government funded research and development project called PancAlert, which provide us non-refundable grant income that covers a percentage of the individual project-related costs.

 

Results of Operations

 

Comparison of the Six Months Ended June 30, 2024 and 2023

 

The following table provides certain selected financial information for the periods presented:

 

		Six Months Ended June 30,												%
		2024				2023				Change				Change
Revenue		$	520,773			$	499,049			$	21,724				4	%
Cost of revenue		$	201,735			$	211,310			$	(9,575	)			(5	)%
Gross profit		$	319,038			$	287,739			$	31,299				11	%
Gross margin			61	%			58	%
Research and development		$	3,242,622			$	5,481,229			$	(2,238,607	)			(41	)%
Sales and marketing		$	2,361,105			$	3,992,975			$	(1,631,870	)			(41	)%
General and administrative		$	4,522,639			$	5,227,181			$	(704,542	)			(13	)%
Total operating expenses		$	10,126,366			$	14,701,385			$	(4,575,019	)			(31	)%
Loss from operations		$	(9,807,328	)		$	(14,413,646	)		$	(4,606,318	)			(32	)%
Other expense		$	(1,216,434	)		$	(398,997	)		$	817,437				205	%
Net loss		$	(11,023,762	)		$	(14,812,643	)		$	(3,788,881	)			(26	)%
Total comprehensive loss		$	(11,086,128	)		$	(14,963,239	)		$	(3,877,111	)			(26	)%
Basic and dilutive loss per common share		$	(0.49	)		$	(1.00	)		$	0.51				51	%
Weighted average number of common shares outstanding – basic and diluted			22,350,033				14,803,243

 

 

 

Revenue

 

Revenue for the six months ended June 30, 2024 was $520,773 as compared to $499,049 for the six months ended June 30, 2023, an increase of 4%. This increase was attributable to ColoAlert sales, primarily in Germany. We intend to continue our efforts to grow the market for ColoAlert, both in Germany and extending to other countries in Europe.

  

Cost of Revenue

 

Cost of revenue for the six months ended June 30, 2024 was $201,735 as compared to $211,310 for the six months ended June 30, 2023, a 5% decrease. This decrease was the result of increased ColoAlert sales volume, which drove efficiencies across our fixed costs, lowering overall unit costs.

 

Gross profit

 

Gross profit increased to $319,038 in the six months ended June 30, 2024 compared to $287,739, for the six months ended June 30, 2023. This gross profit increase, resulting in an improvement of gross margin from 58% to 61%, was attributable to improved profits resulting from lowered unit cost of goods sold attributable to economies of scale with increased sales volumes.

 

Research and Development Expenses

 

Research and development expenses for the six months ended June 30, 2024 were $3,242,622 compared to $5,481,229 for the six months ended June 30, 2023, a decrease of $2,238,607. This decrease was driven by the cost of our ColoFuture and eAArly Detect feasibility studies in the U.S. and in Europe, which drove significant expenses in the first six months of 2023 compared to the same period in 2024. During the six months ended June 30, 2023, clinical study expenses and professional fees related to those studies were $2.8 million compared to $0.6 million in the six months ended June 30, 2024.

 

Sales and Marketing Expenses

 

Sales and marketing expenses for the six months ended June 30, 2024, were $2,361,105 compared to $3,992,975 for the six months ended June 30, 2023, a decrease of $1,631,870. This decrease was related to a decrease in our marketing and advertising expense of $1.3 million as we focused more of our efforts on sales to our lab partners as opposed to online marketing for consumer sales. Accompanying this decrease, we reduced labor costs (salary and consulting) in line with our shift in focus away from consumer sales.

 

General and Administrative Expenses

 

General and administrative expenses for the six months ended June 30, 2024 were $4,522,639 compared to $5,227,181 for the six months ended June 30, 2023, a decrease of $704,542. The decreased expenses were primarily the result of a decrease of $640,290 of non-cash stock option expense for the six months ended June 30, 2024 compared to the same period in 2023.

 

Other Expense

 

Other expense, net for the six months ended June 30, 2024 was $1,216,434 compared to $398,997 for the six months ended June 30, 2023, resulting in increased other expenses (net) of $817,437. This increase was primarily the result of increased interest expense of $0.6 million from the Company’s higher convertible debt balances and the increase in the fair value adjustment of $0.6 million, mitigated by a non-recurring financing expense of $0.3 million recorded in the first six months of 2023.

 

Liquidity and Capital Resources

 

Our principal liquidity requirements are for working capital and operating losses. We fund our liquidity requirements primarily through cash on hand, cash flows from operations and, debt and equity financing. As of June 30, 2024, we had $977,764 of cash and cash equivalents, with $7,070,925 as of December 31, 2023.

 

 

The following table summarizes our cash flows from operating, investing and financing activities:

 

		Six Months Ended June 30,
		2024				2023				Change
Cash used in operating activities		$	(8,144,745	)		$	(10,778,125	)		$	(2,633,380	)
Cash used in investing activities		$	(420,660	)		$	(1,524,555	)		$	(1,103,895	)
Cash provided by financing activities		$	2,551,325			$	6,192,507			$	(3,641,182	)

 

Cash Flow from Operating Activities

 

For the six months ended June 30, 2024, cash flows used in operating activities was $8,144,745 compared to $10,778,125 used during the six months ended June 30, 2023. The improvement in cash flows used in operating activities of $2,633,380 was primarily the result of our smaller operating loss for the six months ended June 30, 2024, net of non-cash stock-based compensation, depreciation and amortization, and timing differences for the settlement of assets and liabilities, as compared to the six months ended June 30, 2023.

 

Cash Flows from Investing Activities

 

During the six months ended June 30, 2024, we used $420,660 in investing activities compared to $1,524,555 used during the six months ended June 30, 2023. The decrease in cash flows used in investing activities of $1,103,895 was the primarily the result of higher capital expenditures during the six months ended June 30, 2023 related to the expansion of our office and lab space. During the first six months of 2024, the Company did not incur significant costs related to the development of the new lab space as it was awaiting local government approvals on the work done to date.

 

Cash Flows from Financing Activities

 

During the six months ended June 30, 2024, we had cash flow provided by financing activities of $2,551,325 compared to cash flow provided by financing activities of $6,192,507 for the six months ended June 30, 2023, a decrease of $3,641,182. This decrease was primarily the result of the Company closing a $5.5 million convertible note transaction in the first six months of 2023 and a $3.3 million convertible note transaction in the first six months of 2024. In addition the amount raised by the Company from the sale of ordinary shares decreased by $1.4 million in the six months ended June 30, 2024 compared to the six months ended June 30, 2023.

 

Working Capital Discussion

 

We had recurring losses, accumulated deficit totaling $80,351,783 and negative cash flows used in operating activities of $8,144,745 as of and for the six months ended June 30, 2024. We also had $977,764 of cash on hand on June 30, 2024, and a working capital deficit, excluding liabilities expected to be settled with ordinary shares, of $1,782,238.

 

These conditions are indicators that impact the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. If the Company is unable to obtain funding, the Company could be forced to further delay, reduce or eliminate its research and development, regulatory, and commercial efforts which could adversely affect its future business prospects and its ability to continue as a going concern.

 

We plan to fund our cash flow and working capital needs through current cash on hand and future debt and/or equity financings which we may obtain through one or more public or private equity offerings, debt financings, government or other third-party funding, strategic alliances or collaboration agreements. During 2023, the Company raised $16.5 million from a combination of sale of shares and warrants as well as the issuance of convertible debt. During the first six months of 2024, the Company raised $3.5 million of net proceeds from the issuance of a convertible note and through the sales of ordinary shares. The Company believes that it will be able to raise additional funds through a combination of the sale of ordinary shares, the sale and/or conversion of warrants, and use of the Company’s access to capital through its Controlled Equity Offering and its Pre-Paid Advance Agreement. The Company also has the ability to defer certain costs, especially those related to clinical studies, to match financing inflows. During July 2024 and October 2024, the Company restructured its operations to focus on its ColoAlert business in Europe, the development of its next generation product, and planning for the Early Detect 2 clinical study in the U.S. in 2025. In line with that focus, the Company implemented cost reduction efforts which included the reduction of its operating costs, including the reduction of personnel by 65%, reduction of external consulting costs, and the sale/closure of its European Oncology Lab (“EOL”) business in St. Ingbert, Germany. Additionally, the Company amended the employment contracts of its CEO and CFO, reducing the salaries of those officers to 60% and 50% of their original salaries, respectively, effective November 1, 2024. The Company believes that these cost reductions will best position our business for 2025 and beyond. The Company believes that its currently available cash on hand, including additional financing described above, will be sufficient to meet its planned expenditures and to meet the Company’s obligations for at least the one-year period following its consolidated financial statement issuance date.

 

 

Our consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities, the reported revenues and expenses, and the statement of financial position classifications used, that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.

 

Critical Accounting Policies and Significant Judgments and Estimates

 

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our significant accounting policies are described in more detail in the notes to our financial statements included elsewhere in this prospectus, we believe that the following accounting policies are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

 

We believe our most critical accounting policies and estimates relate to the following:

 

●

Revenue Recognition;

 

●

Foreign Currency Translation;

 

●

Stock Option Compensation;

 

●

Lease Accounting; and

 

●

Financial Instruments.

 

Revenue Recognition

 

Our revenue is primarily derived through providing our ColoAlert genetic diagnostic test kits to customers. We recognize revenue in accordance with International Financial Reporting Standards (“IFRS”) 15 “Revenue from Contracts with Customers”.

 

In accordance with IFRS 15, revenue is recognized upon the satisfaction of performance obligations. Performance obligations are satisfied at the point at which control of the promised goods or services are transferred to customers, in an amount that reflects the consideration we expect to be entitled to receive for those goods and services.

 

 

We provide a genetic diagnostic testing service and testing kits which are not considered separately identifiable from each other as we use the testing kits to collect samples in order to deliver the diagnostic test results to the customer. Accordingly, we have one performance obligation which is fulfilled upon the delivery of the test results to the customer and revenue is recognized at that point in time.

 

We also receive income from government sponsored R&D grants. Income is recognized on these programs when funds are received and all performance obligations, as defined in the grant, are completed. This income is included in the Statements of Comprehensive Loss as Other Income.

 

Foreign Currency Translation

 

The functional currency is determined using the currency of the primary economic environment in which that entity operates. The functional, as determined by our management, is the Euro (EUR).

 

Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

 

Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in the statement of comprehensive loss in the period in which they arise, except where deferred in equity as a qualifying cash flow or net investment hedge.

 

Exchange differences arising on the translation of non-monetary items are recognized in other comprehensive income to the extent that gains and losses arising on those non-monetary items are also recognized in other comprehensive income. Where the non-monetary gain or loss is recognized in profit or loss, the exchange component is also recognized in profit or loss.

 

Our reporting currency is the US dollar. For presentation purposes, all amounts are translated from the Euro functional currency to the US dollar presentation currency for each period using the exchange rate at the end of each reporting period for the statement of financial position. Revenues and expenses are translated on the basis of average exchange rates during the year.

 

Exchange gains and losses arising from translation to our presentation currency are recorded as exchange differences on translation to reporting currency, which is included in other comprehensive income (loss).

 

Stock Option Compensation

 

We have adopted our 2021 Omnibus Incentive Plan and 2022 Omnibus Incentive Plan (the (“Plans”). Under the Plans, we are authorized to issue equity incentives in the form of incentive stock options, non-statutory stock options, restricted shares, restricted share units, share appreciation rights, performance units or performance shares under separate award agreements. Under the Plans, the aggregate number of shares underlying awards that we could issue cannot exceed, 2,800,000 ordinary shares.

 

On November 4, 2021, we awarded 1,484,650 stock options under the Plans, with a strike price of $5.00, the per share price in our November 2021 initial public offering. Such stock options were granted to all of our current employees, directors, advisors and senior management team. Such stock options for our non-senior management team, independent directors and advisors will begin vesting on November 4, 2022 and stop vesting on November 4, 2025 at the latest. Such stock options for the four members of our senior management team began vesting in portions equal to 25% of such options granted if, prior to November 4, 2025, the four-year anniversary of our initial public offering, for ten consecutive trading days (with at least 100,000 shares traded per trading day) the volume-weighted average price of the ordinary shares on the principal market is at least:

 

●

$7.50;

 

●

$10.00;

 

 

●

$12.50, provided that such options cannot vest until the twelve-month anniversary of our initial public offering at the earliest; and

 

●

$15.00, provided that such options cannot vest until the twelve-month anniversary of our initial public offering at the earliest.

 

100% of these options were fully vested on November 5, 2022.

 

We have valued these stock options as follows: (a) for those options that have time-based vesting, we will use the Black-Scholes method to value the stock options at the time of award and record the compensation expense in our Statement of Operations over the vesting period, and (b) for options issued with milestone based vesting criteria, we will use a Monte Carlo simulation to value the options at the time of issuance and each subsequent reporting date until fully vested or expired, with any change in compensation expense measured by such method to be recorded in our Statement of Operations.

 

The Black-Scholes option pricing model considers, among other factors, the expected term of the award and the expected volatility of our stock price. Due to the lack of an adequate history of a public market for the trading of our ordinary shares, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded with historical share price information sufficient to meet the expected life of the stock-based awards. The Monte Carlo simulation approach is a class of computational algorithms that rely on repeated random sampling to compute their results. This approach allows the calculation of the value of such stock options based on a large number of possible stock price path scenarios. Expense for the market-condition stock options will be recognized over the derived service period as determined through the Monte Carlo simulation model.

 

Lease Accounting

 

We assess at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. We apply a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. We recognize lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

 

At the commencement date of the lease, we recognize lease liabilities measured at the present value of lease payments to be made over the lease term. Lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. Lease payments also include the exercise price of a purchase option reasonably certain to be exercised by us and payments of penalties for terminating the lease, if the lease term reflects us exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the period in which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, we use our incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset.

 

We recognize right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.

 

 

Financial Instruments

 

(a) Classification

 

We classify our its financial instruments in the following categories: at fair value through profit and loss (“FVTPL”), at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. We determine the classification of financial assets at initial recognition. The classification of debt instruments is driven by our business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition we can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if we have opted to measure them at FVTPL.

 

(b) Measurement

 

Financial assets and liabilities at amortized cost

 

Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment.

 

Financial assets and liabilities at FVTPL

 

Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the statements of loss and comprehensive loss in the period in which they arise.

 

Debt investments at FVTOCI

 

These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss.

 

Equity investments at FVTOCI

 

These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditure or capital resources that is material to investors.

 

 

Exhibit 99.3

 

NOTICE OF EXTRAORDINARY GENERAL MEETING OF

mainz biomed N.V.

 

Notice is given that an extraordinary general meeting of Mainz Biomed N.V., a public company under Dutch law, registered with the Dutch trade register under number 82122571 (the “Company”), will be held at the offices of CMS Netherlands, Atrium, Parnassusweg 737, 1077 DG Amsterdam, the Netherlands, on 13 November 2024 at 14.00 hours Central European Time (the “EGM”).

 

Agenda

 

The agenda for the EGM and related documents and further information regarding the EGM can be found on the Company’s website at https://www.mainzbiomed.com/investors. They are also available for inspection and can be obtained free of charge at the offices of the Company.

 

Record Date

 

The Record Date for the EGM is 16 October 2024. Each share outstanding on the Record Date entitles the holder to cast one vote on each voting item at the EGM.

 

Shareholders of Record

 

Shareholders of Record are those who are shareholders of the Company, or otherwise have voting rights or meeting rights in respect of shares in the capital of the Company, at the Record Date and who are recorded as such in the part of the register of shareholders of the Company, including all records and other data carriers relating thereto, kept by Transhare Corporation, the Company’s transfer agent, irrespective of any changes to the entitlement to their shares or to their voting rights or meeting rights after the Record Date.

 

Beneficial Owners

 

Beneficial Owners are those who beneficially own shares in the capital of the Company through a bank, broker or other nominee on the Record Date.

 

Attendance

 

A Shareholder of Record or Beneficial Owner who wishes to attend the EGM, in person or by a proxy, must notify the Company of its intention to do so by e-mail at ir@mainzbiomed.com no later than 18.00 hours Central European Time on 11 November 2024. The notice must contain the name and the number of shares the Shareholder of Record or Beneficial Owner will represent at the EGM. In addition, a Shareholder of Record or Beneficial Owner who wishes to attend the EGM by a proxy must enclose its signed proxy. A proxy can be downloaded from the website of the Company at https://www.mainzbiomed.com/investors.

 

A Beneficial Owner must also enclose:

 

(a)	proof of its beneficial ownership of the relevant shares, for instance a recent account statement; and

 

(b)

a signed proxy from the bank, broker or other nominee registered in the part of the register of shareholders of the Company, including all records and other data carriers relating thereto, kept by Transhare Corporation as the holder of the relevant shares on the Record Date, confirming that the Beneficial Owner is authorised to attend and vote at the EGM.

 

 

Beneficial Owners should contact their bank, broker or other nominee to obtain such a proxy from them.

 

Any notice of attendance, proof of beneficial ownership or signed proxy received after 18.00 hours Central European Time on 11 November 2024 will be disregarded. Shareholders of Record, Beneficial Owners and proxyholders who have not complied with the procedures described above may be refused entry to the EGM.

 

All attendees must be prepared to show a valid proof of identity for admittance.

 

To avoid misunderstandings, the procedures outlined above do not apply with respect to proxy cards solicited through Broadridge, the Company’s proxy solicitor. Shareholders of Record using such a proxy card should follow the instructions and observe the deadlines specified on the proxy card they receive.

 

How to vote

 

Shareholders of Record and Beneficial Owners may vote in person or by proxy at the EGM in accordance with the procedures described above.

 

Beneficial Owners may also have their shares voted by following the procedures specified on their broker’s voting instruction form. Shortly before the EGM, the brokers will tabulate the votes they have received and submit one or more proxy cards to the Company reflecting the aggregate votes of the Beneficial Owners.

 

Contact details

 

For further information please contact the Company’s Investor Relations Department by e-mail at ir@mainzbiomed.com.

 

 

Exhibit 99.4

 

 

AGENDA of the extraordinary GENERAL MEETING OF mainz biomed N.V.

 

Agenda of the extraordinary general meeting of Mainz Biomed N.V., a public company under Dutch law, registered with the Dutch trade register under number 82122571 (the “Company”), to be held at the offices of CMS, Atrium, Parnassusweg 737, 1077 DG Amsterdam, the Netherlands, on 13 November 2024 at 14.00 hours Central European Time (the “EGM”).

 

1.	Opening
2.	Authorisation of amendment of articles of association, reverse stock split, and authorisation for execution of deed of amendment of articles of association		Voting item
3.	Other matters for discussion
4.	Close

 

 

EXPLANATORY NOTES TO THE AGENDA of the extraordinary GENERAL
MEETING OF mainz biomed N.V.

 

1.

Opening

 

2.	Authorization of amendment of articles of association, reverse stock split and authorisation for execution deed of amendment of articles of association

 

Reverse stock split

 

It is proposed to authorise the board of directors of the Company (the “Board”), in its discretion, to effect a reverse stock split within a range between 2:1 and 100:1.

 

The primary purpose for effecting the reverse stock split would be to increase the per-share trading price of the Company’s ordinary shares to maintain their listing on the Nasdaq Stock Market. The Nasdaq Listing Rules require that listed shares maintain a minimum bid price of USD 1.00 per share (the “Minimum Bid Price Requirement”). As previously reported, on 28 May 2024, the Company received a deficiency letter from the Nasdaq Listing Qualifications Department notifying the Company that, for the last 30 consecutive business days, the Company did not meet the Minimum Bid Price Requirement. The Company has been provided an initial period of 180 calendar days, or until 25 November 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement.

 

If at any time during this 180-day period the closing bid price of the Company’s ordinary shares is at least USD 1.00 per share for a minimum of ten consecutive business days, the Nasdaq Listing Qualifications Department will provide the Company written confirmation that it complies with the Minimum Bid Price Requirement and the ordinary shares will continue to be eligible for listing on The Nasdaq Capital Market.

 

In the event the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Nasdaq Listing Qualifications Department will inform the Company that it has been granted an additional 180 calendar days.

 

By granting the Company the flexibility to effect a reverse stock split, the Company will have a contingency plan to increase the share price of the ordinary shares above USD 1.00 in the event that it does not regain compliance with the Minimum Bid Price Requirement prior to the Compliance Date or, if secured, within a second period of 180 days. For the 30 trading days during the period 22 August 2024 to 3 October 2024 prior to the publication of these explanatory notes, the closing bid price of the Company’s ordinary shares has ranged from USD 0.43 to USD 0.20, with an average closing bid price of USD 0.30.

 

The Board has considered the potential harm to the Company and its shareholders should Nasdaq delist the Company’s ordinary shares. Delisting could adversely affect the liquidity of the Company’s ordinary shares since alternatives are generally considered to be less liquid markets. An investor likely would find it less convenient to sell, or to obtain accurate quotations in seeking to buy, the Company’s ordinary shares on an over-the-counter market. Further, many investors likely would not buy or sell the Company’s ordinary shares due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or for other reasons.

 

 

If and when the Board determines to implement the reverse stock split, the reverse stock split ratio will be set within a range between 2:1 and 100:1 (the “Split Ratio Range”) subject to the proviso that the reverse stock split will be implemented in such a way that it does not entail a capital reduction. The Board is authorised to do whatever is necessary to avoid a capital reduction. If the reverse stock split is implemented, the reverse stock split ratio as set by the Board will be announced in accordance with applicable laws.

 

If the EGM authorises the Board to effect a reverse stock split, the Board will have the sole authority to elect, at any time prior to the annual general meeting of the Company to be held in 2025, whether or not to effect a reverse stock split. The Board will have the flexibility to decide whether or not a reverse stock split, and at what ratio within the Split Ratio Range, is in the Company’s best interests.

 

Upon effectiveness of the reverse stock split, each shareholder will own a reduced number of ordinary shares. However, the Company expects that the market price of the ordinary shares immediately after the reverse stock split will increase above the market price of the ordinary shares immediately prior to the reverse stock split, which is designed to help the Company to regain and maintain compliance with the Minimum Bid Price Requirement. The proposed reverse stock split will be effected simultaneously for all of the ordinary shares and the ratio for the reverse stock split, once determined, will be the same for all of the ordinary shares. Ïhe reverse stock split will affect all shareholders uniformly and will not affect any shareholder’s percentage ownership interest in the Company, except to the extent that the reverse stock split would result in any of the shareholders owning a fractional interest as described below. Likewise, the reverse stock split will affect all holders of outstanding equity awards under the Company’s equity incentive plans substantially the same, except to the extent that the reverse stock split would result in a fractional interest as described below. Proportionate voting rights and other rights of the holders of ordinary shares will not be affected by the proposed reverse stock split, except to the extent that the reverse stock split would result in any shareholders owning a fractional interest as described below.

 

The nominal value per ordinary share would be adjusted from EUR 0.01 per share before the reverse stock split to a proportionately increased nominal value per share after the reverse stock split, based on the final reverse stock split ratio, as described below.

 

The ordinary shares are currently registered under section 12(b) of the U.S. Securities and Exchange Act of 1934 (the “Exchange Act”), and the Company is subject to the periodic reporting and other requirements of the Exchange Act. The reverse stock split will not affect the registration of the ordinary shares under the Exchange Act.

 

Shares that are held in registered form will be consolidated and converted into shares based on the new nominal value to be determined in accordance with the final reverse stock split ratio. Fractional shares created as a result of the consolidation and conversion will be subject to the rights specified in article 4.5, 29.2 and 31.1 of the articles of association of the Company contained in the draft of the deed of amendment of articles of association referred to below.

 

Shares that are held through the facilities of Cede & Co. as nominee for the Depositary Trust Company will be consolidated and converted into a rounded down number of whole shares and the holders will receive a cash-in-lieu of fractional shares payment from their bank or intermediary.

 

 

Amendment articles of association

 

Furthermore, for the purpose of effecting the reverse stock split, it is proposed to approve the amendment of the Company’s articles of association in accordance with the draft of the deed of amendment of articles of association drawn up by CMS Derks Star Busmann N.V. in connection with the EGM and published on the Company’s website.

 

The amount of the authorised capital will be derived from the reverse stock split ratio as set by the Board subject to the proviso that it will not be more than five times the issued capital, as prescribed by Dutch law. The authorised share capital will be divided nine-tenths into ordinary shares and one-tenth into preferred shares. Ordinary shares and preferred shares will have the same nominal value. There are no preferred shares outstanding at the moment.

 

The proposed amendment to the articles of association will not change the terms of the ordinary shares. After the reverse stock split, the ordinary shares will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the ordinary shares now authorised. The ordinary shares issued pursuant to the reverse stock split will remain fully paid and nonassessable. Following the reverse stock split, the Company will continue to be subject to the periodic reporting requirements of the Exchange Act.

 

Authorisation for execution of deed of amendment of articles of association

 

Finally, it is proposed that each director of the Company and each civil law notary, assigned civil law notary, candidate civil law notary, notarial assistant and notarial secretary working with CMS Derks Star Busmann N.V. be authorised to have the deed of amendment of articles of association executed and to perform all other legal acts which the authorised person deems necessary in connection therewith.

 

3.

Other matters for discussion

 

4.

Close

 

 

4

 

Exhibit 99.5

 

VOTING PROXY

 

THE UNDERSIGNED

 

Name:
Address:
Postal code and city:
Country:
Guidance note: To be further completed only if relevant
Acting on behalf of:
Name:
Legal form:
Country of incorporation:
Address:
Postal code and city:
Country:

(the “Principal”).

 

GRANTS POWER OF ATTORNEY to

 

Guidance note: Please check the applicable box below.
☐	each director of the Company
☐	each civil law notary, assigned civil law notary and candidate civil law notary working with CMS Derks Star Busmann N.V., Dutch counsel to the Company
☐
	Guidance note: Possibility to fill in above the name of an authorised person of your own choice.

 

for the performance in the Principal’s name, in its capacity as shareholder of Mainz Biomed N.V., a public company under Dutch law, registered with the Dutch trade register under number 82122571 (the “Company”), of the following legal acts:

 

(a)	representing the Principal at the extraordinary general meeting of the Company to be held at the offices of CMS, Atrium, Parnassusweg 737, 1077 DG Amsterdam, the Netherlands, on 13 November 2024 at 14.00 hours CET (the “EGM”);

 

(b)	attending and addressing the EGM;

 

(c)

exercising at the EGM the voting rights attached to the shares in the capital of Company held by the Principal on the record date for the EGM set or to be set by the board of the Company, and voting in favour of all proposals included in the agenda for the EGM, unless clearly indicated otherwise below:

 

No.	Agenda item
2.	Reverse stock split, amendment of articles of association and authorisation execution of deed of amendment of articles of association
	For:	☐	Number of shares:
	Against:	☐	Number of shares:
	Abstain:	☐	Number of shares:

 

 

ON THE FOLLOWING TERMS

 

1.	Each Authorised Person shall be authorised to grant the power of attorney granted to him to any other person, whereupon such other person will for the purpose of this power of attorney be deemed to be an Authorised Person as well.

 

2.	This power of attorney shall be exclusively governed by and construed in accordance with Dutch law.

 

SIGNED AS FOLLOWS

 

(Signature page follows)

 

 

(Signature page to power of attorney)
Name:
Date:

 

 

v3.24.3

Document And Entity Information	6 Months Ended
	Jun. 30, 2024
Document Information Line Items
Entity Registrant Name	MAINZ BIOMED N.V.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001874252
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity File Number	001-41010

v3.24.3

Consolidated Statements of Financial Position (Unaudited) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets
Cash	$ 977,764	$ 7,070,925
Trade and other receivables, net	139,414	93,555
Inventories	520,531	613,638
Prepaid expenses and other current assets	751,994	1,201,778
Total Current Assets	2,389,703	8,979,896
Property and equipment, net	1,625,373	1,702,317
Intangible assets	3,206,054	3,394,645
Right-of-use assets	1,232,900	1,332,170
Total assets	8,454,030	15,409,028
Current Liabilities
Accounts payable and accrued liabilities	2,903,873	3,184,381
Accounts payable - related party	426,637	299,936
Deferred revenue	116,679	138,889
Convertible debts	5,842,003	4,903,310
Convertible debt - related party	32,140	33,118
Silent partnerships	49,036
Intellectual property acquisition liability - related party	324,003	388,839
Lease liabilities	319,573	288,463
Total current liabilities	10,013,944	9,236,936
Silent partnerships	713,856	758,812
Silent partnerships - related party	267,206	271,354
Lease liabilities	1,046,163	1,165,723
Intellectual property acquisition liability - related party	551,561	726,977
Total Liabilities	12,592,730	12,159,802
Shareholders’ equity (deficit)
Share capital	276,378	235,818
Share premium	54,136,785	51,507,526
Reserve	22,314,598	21,286,215
Accumulated deficit	(80,351,783)	(69,328,021)
Accumulated other comprehensive loss	(514,678)	(452,312)
Total shareholders’ equity (deficit)	(4,138,700)	3,249,226
Total liabilities and shareholders’ equity (deficit)	$ 8,454,030	$ 15,409,028

v3.24.3

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Profit or loss [abstract]
Revenue	$ 520,773	$ 499,049
Cost of sales	201,735	211,310
Gross margin	319,038	287,739
Operating expenses:
Sales and marketing	2,361,105	3,992,975
Research and development	3,242,622	5,481,229
General and administrative	4,522,639	5,227,181
Total operating expenses	10,126,366	14,701,385
Loss from operations	(9,807,328)	(14,413,646)
Other income (expense)
Other income	105,851	125,968
Change in fair value of convertible debt	(528,210)	45,000
Financing expense		(250,000)
Interest and accretion expense	(659,473)	(88,759)
Other expense	(134,602)	(231,206)
Total other expense, net	(1,216,434)	(398,997)
Loss before income tax	(11,023,762)	(14,812,643)
Income taxes provision
Net loss	(11,023,762)	(14,812,643)
Foreign currency translation loss	(62,366)	(150,596)
Comprehensive loss	$ (11,086,128)	$ (14,963,239)
Basic loss per ordinary share (in Dollars per share)	$ (0.49)	$ (1)
Diluted loss per ordinary share (in Dollars per share)	$ (0.49)	$ (1)
Weighted average number of ordinary shares outstanding (in Shares)	22,350,033	14,803,243

v3.24.3

Consolidated Statement of Changes in Shareholders’ Equity (Deficit) (Unaudited) - USD ($)	Share Capital	Share Premium	Reserve	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2022	$ 164,896	$ 38,831,542	$ 18,079,741	$ (43,032,294)	$ 52,182	$ 14,096,067
Balance (in Shares) at Dec. 31, 2022	14,629,457
Sale of ordinary shares	$ 3,318	1,889,878				1,893,196
Sale of ordinary shares (in Shares)	307,365
Share based expense	$ 375	177,315				177,690
Share based expense (in Shares)	34,500
Ordinary shares issued for acquisition of intangible asset	$ 3,270	2,051,730				2,055,000
Ordinary shares issued for acquisition of intangible asset (in Shares)	300,000
Ordinary shares issued for commission of issuance of convertible debt	$ 593	249,407				250,000
Ordinary shares issued for commission of issuance of convertible debt (in Shares)	54,428
Ordinary shares issued for cashless exercise of warrant	$ 3,333	12,132	(15,465)
Ordinary shares issued for cashless exercise of warrant (in Shares)	305,771
Stock option expense			1,668,673			1,668,673
Net loss				(14,812,643)		(14,812,643)
Foreign currency translation					(150,596)	(150,596)
Balance at Jun. 30, 2023	$ 175,785	43,212,004	19,732,949	(57,844,937)	(98,414)	5,177,387
Balance (in Shares) at Jun. 30, 2023	15,631,521
Balance at Dec. 31, 2023	$ 235,818	51,507,526	21,286,215	(69,328,021)	(452,312)	3,249,226
Balance (in Shares) at Dec. 31, 2023	21,165,482
Sale of ordinary shares	$ 9,679	505,583				515,262
Sale of ordinary shares (in Shares)	1,055,000
Issuance of ordinary shares for conversion of debt	$ 30,881	2,123,676				2,154,557
Issuance of ordinary shares for conversion of debt (in Shares)	3,366,093
Stock option expense			1,028,383			1,028,383
Net loss				(11,023,762)		(11,023,762)
Foreign currency translation					(62,366)	(62,366)
Balance at Jun. 30, 2024	$ 276,378	$ 54,136,785	$ 22,314,598	$ (80,351,783)	$ (514,678)	$ (4,138,700)
Balance (in Shares) at Jun. 30, 2024	25,586,575

v3.24.3

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows From Operating Activities
Net loss	$ (11,023,762)	$ (14,812,643)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation	1,028,383	2,096,363
Depreciation and amortization	496,948	458,368
Bad debt expense	16,090	53,295
Inventory write down	67,080
Accretion expense	81,361	88,759
Change in fair value of convertible debt	528,210	(45,000)
Changes in operating assets and liabilities:
Trade and other receivables, net	(64,949)	58,898
Inventories	8,271	(208,367)
Prepaid expenses and other assets	450,658	372,018
Accounts payable and accrued liabilities	285,161	1,161,515
Deferred revenue	(18,196)	(1,331)
Net cash used in operating activities	(8,144,745)	(10,778,125)
Cash Flows From Investing Activities
Payment for intellectual property acquisition liability	(300,000)	(500,000)
Purchase of property and equipment	(120,660)	(1,024,555)
Net cash used in investing activities	(420,660)	(1,524,555)
Cash Flows From Financing Activities
Sale of ordinary shares and warrants	515,262	1,894,742
Proceeds of convertible debt	2,970,000	5,060,000
Repayments from convertible debt	(787,633)
Payments on loan payable		(560,755)
Payments of lease obligations	(146,304)	(201,480)
Net cash provided by financing activities	2,551,325	6,192,507
Effect of changes in exchange rates	(79,081)	(120,515)
Net change in cash	(6,093,161)	(6,230,688)
Cash at beginning of period	7,070,925	17,141,775
Cash at end of period	977,764	10,911,087
Cash Paid For:
Income tax
Interest expense	190,000	104,822
Non-Cash Investing and Financing Activities
Right of use asset additions	100,578	969,813
Acquisition of intangible asset for debt and stock payable		3,271,828
Issuance of ordinary shares for conversion of debt	$ 2,154,557

v3.24.3

Nature of Operations and Going Concern	6 Months Ended
	Jun. 30, 2024
Nature of Operations and Going Concern [Abstract]
NATURE OF OPERATIONS AND GOING CONCERN	1. NATURE OF OPERATIONS AND GOING CONCERN   Mainz Biomed N.V. (the “Company”) is domiciled in Netherlands. The Company’s registered office is at Robert-Koch Strasse 50, 55129 Mainz, Germany with substantially all of its operations in Germany. The Company was formed to acquire the business of Mainz Biomed Germany GmbH (f/k/a PharmGenomics GmbH (“PharmaGenomics”, “PG”)). In September 2021, the Company completed a Contribution Agreement to effect such acquisition.   We develop and sell in-vitro diagnostic (“IVD”) tests for the early detection of cancer. Our flagship ColoAlert product is being marketed and sold in European markets. We are currently developing our next generation colorectal cancer screening product and intend to launch that product in the future in the United States and in Europe. We additionally operate a clinical diagnostic laboratory and distribute our IVD kits to third-party laboratories in Europe and through our on-line store in Germany.   Throughout these consolidated financial statements, Mainz Biomed N.V. and its directly and indirectly wholly owned subsidiaries, Mainz Biomed USA, Inc, Mainz Biomed GmbH (f/k/a PharmGenomics GmbH) and European Oncology Lab GmbH are referred to, collectively and individually as “Mainz”, “Mainz Biomed”, or the “Company”).   Going Concern   The Company has recurring losses, accumulated deficit totaling $80.4 million and negative cash flows used in operating activities of $8.1 million as of and for the six months ended June 30, 2024. The Company also had $977,764 of cash on hand at June 30, 2024. These factors raise a substantial doubt as to the Company’s ability to continue as a going concern for a period that is one year from the date these financial statements are published. If the Company is unable to obtain funding, the Company could be forced to delay, reduce, or eliminate its research and development, regulatory, and commercial efforts which could adversely affect its future business prospects and its ability to continue as a going concern.   Management plans to fund its cash flow needs through current cash on hand and future debt and/or equity financings which it may obtain through one or more public or private equity offerings, debt financings, government or other third-party funding, strategic alliances, or collaboration agreements. During 2023, the Company raised $16.5 million from a combination of sale of shares and warrants as well as the issuance of convertible debt. During the first six months of 2024, the Company raised $3.5 million of net proceeds from the issuance of a convertible note and through the sales of ordinary shares. The Company believes that it will be able to raise additional funds through a combination of the sale of ordinary shares, the sale and/or exercise of warrants, and use of the Company’s access to capital through its Controlled Equity Offering and its Pre-Paid Advance Agreement (see Note 12). The Company also has the ability to defer certain costs, especially those related to clinical studies, to match financing inflows. Subsequent to June 30, 2024, the Company took action to reduce its operating costs, which included the reduction of personnel by 65%, reduction of external consulting costs, and the sale/closure of its European Oncology Lab business in St. Ingbert, Germany (see Note 20). The Company believes that its currently available cash on hand, including additional financing described above, will be sufficient to meet its planned expenditures and to meet the Company’s obligations for at least the one-year period following its consolidated financial statement date.   These consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities, the reported revenues and expenses, and the statement of financial position classifications used, that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.

v3.24.3

Basis of Presentation	6 Months Ended
	Jun. 30, 2024
Basis of Presentation [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION   Basis of Presentation and Statement of Compliance   These condensed interim financial statements have been prepared in accordance with International Accounting Standards (“IAS”) 34, “Interim Financial Reporting” using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and International Financial Reporting Interpretations Committee (“IFRIC”). These condensed interim financial statements do not include all of the information required of a full set of annual financial statements and are intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that these condensed interim financial statements be read in conjunction with the annual financial statements of the Company for the year ended December 31, 2023 and notes thereto contained in the Company’s annual report filed on Form 20-F.    These condensed interim financial statements have been prepared on a historical cost basis, modified where applicable. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting except for cash flow information.   The condensed unaudited interim financial statements were authorized for issuance by the Audit Committee of the Board of Directors on October 17, 2024.   New Accounting Standards   Standards, interpretations and amendments to standards and interpretations in the reporting period not yet effective and not yet applied:   ● In April 2024, the International Accounting Standards Board issued IFRS 18, Presentation and Disclosure in the Financial Statements, which sets out the overall requirements for presentation and disclosures in the financial statements. The new standard will replace IAS 1, Presentation of Financial Statements. Although much of the substance of IAS 1, Presentation of Financial Statements, will carry over into the new standard, the new standard incrementally will:   o With a view to improving comparability amongst entities, require presentation in the statement of operations of a subtotal for operating profit and a subtotal for profit before financing and income taxes (both subtotals as defined in the new standard);   o Require disclosure and reconciliation, within a single financial statement note, of management-defined performance measures that are used in public communications to share management’s views of various aspects of an entity’s performance and which are derived from the statements of income and other comprehensive income;   o Enhance the requirements for aggregation and disaggregation of financial statement amounts; and   o Require limited changes to the statement of cash flows, including elimination of options for the classification of interest and dividend cash flows.   The new standard is effective for annual reporting periods beginning on or after January 1, 2027, with earlier adoption permitted. We are currently assessing the impacts of the new standard; while there will be shifts of where a number of our management-defined performance measures are disclosed and reconciled (primarily a shift from management’s discussion and analysis to the financial statements) and where certain cash flows will be categorized in our statements of cash flows (primarily a shift of interest paid from operating activities to financing activities), we do not expect that the totality of our financial disclosure will be materially affected by the application of the new standard.   ● In May 2024, the International Accounting Standards Board issued Amendments to the Classification and Measurement of Financial Instruments (Amendments to IFRS 9 and IFRS 7). The narrow-scope amendments are to address diversity in accounting practice in respect of the classification of financial assets with environmental, social and corporate governance and similar features; and to clarify the date on which a financial asset or financial liability is derecognized when using electronic payment systems. The new standard is effective for annual reporting periods beginning on or after January 1, 2026, with earlier adoption permitted. We are currently assessing the impacts of the new standard but do not expect to be materially affected by the application of the amendments.

v3.24.3

Summary of Significant Accounting Policies and Use of Estimates and Judgments	6 Months Ended
	Jun. 30, 2024
Summary of Significant Accounting Policies and Use of Estimates and Judgments [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS   Inventories   Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on a weighted average cost and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.   Property and Equipment   Property and equipment are recorded at cost less accumulated depreciation. Expenditures that extend the life of the asset are capitalized and depreciated. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Construction in progress is not depreciated until ready for use. Management evaluates the useful lives and method of depreciation at least annually and accounts for any changes to the useful life or method prospectively. Maintenance and repairs are charged to expense as incurred; cost of major additions and betterments are capitalized.   The estimated useful lives are:   Laboratory equipment   5 – 10 years Office equipment   3 – 10 years   Impairment of Non-Financial Assets   The Company performs impairment tests on its long-lived assets, including property and equipment when new events or circumstances occur, or when new information becomes available relating to their recoverability. When the recoverable amount of each separately identifiable asset or cash generating unit (“CGU”) is less than its carrying value, the asset or CGU’s assets are written down to their recoverable amount with the impairment loss charged against profit or loss. A reversal of the impairment loss in a subsequent period will be charged against profit or loss if there is a significant reversal of the circumstances that caused the original impairment. The impairment will be reversed up to the amount of depreciated carrying value that would have otherwise occurred if the impairment loss had not occurred.   The CGU’s recoverable amount is evaluated using fair value less costs to sell calculations. In calculating the recoverable amount, the Company utilizes discounted cash flow techniques to determine fair value when it is not possible to determine fair value from active markets or a written offer to purchase. Management calculates the discounted cash flows based upon its best estimate of a number of economic, operating, engineering, environmental, political and social assumptions. Any changes in the assumptions due to changing circumstances may affect the calculation of the recoverable amount. There was no impairment recognized in the consolidated financial statements for the year ended December 31, 2023 or the six months ended June 30, 2024.   Leases   The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration, the Company has the right to obtain substantially all of the economic benefits from the use of the asset through the specified period, and the Company has the right to direct the use of the specified assets, which involves the right to make the decisions that are most relevant to its use. The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets, which are recognized in profit or loss as the expense is incurred.   At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. Lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. Lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the period in which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the rate implicit in the lease, or if not readily determinable, its incremental borrowing rate (“IBR”). After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset. Upon a remeasurement of a lease liability, the Company records a proportionate adjustment to the corresponding right-of-use asset. If the remeasurement results in a reduction of the right-of-use asset to nil, the difference is recorded in the statements of profit or loss in the period of occurrence.   The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated amortization and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are amortized on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.   Revenue Recognition   The Company’s revenue is primarily derived through providing genetic diagnostic tests to customers. The Company recognizes revenue in accordance with IFRS 15–- “Revenue from Contracts with Customers”.   In accordance with IFRS 15, revenue is recognized upon the satisfaction of performance obligations. Performance obligations are satisfied at the point at which control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive for those goods and services.   The Company sells its genetic diagnostic testing kits to both laboratory partners and directly to patients who are the end users of the product. Upon the delivery of our products to laboratory partners the Company has completed its performance obligations and as such revenue is recorded upon delivery. Sales to patients, or end users, where samples are sent to our diagnostic lab for testing and evaluation, are recognized when they are delivered to the end user, returned to our laboratory, and testing results have been delivered. Revenue from these sales is deferred on our Statement of Financial Position until recognition. Revenue is recognised from the sale of testing kits.   Cost of revenue   Cost of revenue consists of patient test kits and laboratory kits sold to laboratory partners and patients. In the case of test performed in our diagnostic laboratory cost of revenue also includes the labor and overhead related to the performance of those tests.   Research and Development   Expenditure on research activities, undertaken with the prospect of gaining new technical knowledge and understanding, is recognized in profit or loss as incurred.   Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labor, overhead costs that are directly attributable to preparing the asset for its intended use, and borrowing costs on qualifying assets. Other development expenditures are recognized in profit or loss as incurred.   Research and development costs incurred subsequent to the acquisition of externally acquired intangible assets and on internally generated intangible assets are accounted for as research and development costs.   Financial Instruments   a) Classification   The Company classifies its financial instruments in the following categories: at fair value through profit and loss (“FVTPL”), at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL.   b) Measurement   Financial assets and liabilities at amortized cost   Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. The Company’s financial assets measured at amortized cost are comprised of its cash and trade and other receivables, net. The Company’s financial liabilities measured at amortized cost are comprised of its accounts payable and accrued liabilities, loans payable, loans payable – related party, convertible debt, convertible debt – related parties, silent partnerships, silent partnerships – related party and lease liabilities.   Financial assets and liabilities at FVTPL   Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the statements of loss and comprehensive loss in the period in which they arise.   Debt instruments at FVTOCI   These assets are initially measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses associated with changes in fair value are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. The Company does not hold any debt instruments at FVTOCI.   Equity instruments at FVTOCI   These assets are initially measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses associated with changes in fair value are recognized in OCI and are never reclassified to profit or loss. The Company does not hold any equity instruments at FVTOCI.   c) Impairment of financial assets at amortized cost   The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the statements of loss and comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.   d) Derecognition   Financial assets   The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity.   Financial liabilities   The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and/or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value.   Gains and losses on derecognition are generally recognized in profit or loss.   Convertible Debt   The Company evaluates at initial recognition of a convertible debt the different components and features of the hybrid instruments and determines whether these elements are equity instruments or embedded derivatives which require bifurcation. In subsequent periods, the liability component is accounted for using (i) the fair value method, or (ii) the effective interest method, based on the expected maturity of the debt. The equity component is not remeasured, while embedded derivatives unless closely related to the host instruments, are recorded at fair value through the Consolidated Statement of Operations unless the convertible debt falls under FVTPL.   Foreign Currency Translation   The functional currency is determined using the currency of the primary economic environment in which that entity operates. The functional currency, as determined by management, of the Company is the Euro (EUR).   Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.   Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in the statement of comprehensive loss in the period in which they arise, except where deferred in equity as a qualifying cash flow or net investment hedge.   Exchange differences arising on the translation of non-monetary items are recognized in other comprehensive income to the extent that gains and losses arising on those non-monetary items are also recognized in other comprehensive income. Where the non-monetary gain or loss is recognized in profit or loss, the exchange component is also recognized in profit or loss.   The Company’s presentation currency is the US dollar. For presentation purposes, all amounts are translated from the Euro functional currency to the US dollar presentation currency for each period using the exchange rate at the end of each reporting period for the statement of financial position. Revenues and expenses are translated on the basis of average exchange rates during the year.   Exchange gains and losses arising from translation to the Company’s presentation currency are recorded as exchange differences on translation to reporting currency, which is included in other comprehensive income (loss).   Income Taxes   Current income tax:   Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income.   Current income tax relating to items recognized directly in other comprehensive income or equity is recognized in other comprehensive income or equity and not in profit or loss. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.   Deferred tax:   Deferred tax is recognized on temporary differences at the reporting date arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.   The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that future taxable income will be available to allow all or part of the temporary differences to be utilized.   Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted and are expected to apply by the end of the reporting period. Deferred tax assets and deferred income tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.   Government Grants   Government grants are recognized when there is reasonable assurance that the grant will be received and that the Company will comply with the conditions attached to them. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as income in equal amounts over the expected useful life of the related asset.   Loans received with better than market terms from government programs are recognized initially at fair value, with the difference between the fair value of the loan based on prevailing market interest rates and the amount received recorded as a gain in the statements of loss and comprehensive loss.   Share-Based Compensation   Our stock option grants may contain time based or market-based vesting provisions. Time based options are expensed on a straight-line basis over the vesting period. Market based options (“MBOs”) are expensed when the related service and market performance conditions are expected to be met, such that the expenses ultimately recognized is based on the number of awards that meet the related service and market performance conditions at the vesting date.   The fair value of the stock options is determined on the grant date and is affected by our stock price and other assumptions regarding a number of complex and subjective variables. These variables include our expected stock price volatility over the term of the awards, risk free interest rates, expected dividends, and the expected option exercise term. The Company estimates the fair value of time-based stock options using the Black-Scholes-Merton pricing model. The simplified method is used to estimate the expected term of stock options due to a lack of related historical data regarding exercise, cancellation, and forfeiture. For MBOs, the fair value is estimated using Monte Carlo simulation techniques.   Where an equity-settled award is cancelled, it is treated as if it vested on the date of the cancellation and any expense not yet recognized for the award (being the total expense as calculated at the grant date) is recognized immediately. This includes any awards where vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and designated as a replacement award on the date that it is granted, the cancelled award and new awards are treated as if they were a modification of the original awards.   Loss per Share   Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. For all periods presented, the loss attributable to common shareholders equals the reported loss attributable to owners of the Company. When calculating the diluted earnings (loss) per share, the Company adds to the average number of ordinary shares outstanding, that was used to calculate the basic earnings per share, the weighted average of the number of shares to be issued assuming that all shares that have a potentially dilutive effect would be converted into shares. Potential ordinary shares are only taken into account in cases where their effect is dilutive (reducing the earnings per share or increasing the loss per share). As the Company has recorded net losses from operations in all periods presented, it has excluded stock options and warrants from the diluted Loss per Share calculation as the exercise of such would be anti-dilutive.   Segment Report   The Company operates in one operating segment, genetic diagnostic testing.   Reclassifications   Certain prior year amounts have been reclassified for consistency with the current year presentation.   Critical Accounting Estimates and Significant Management Judgments   The preparation of financial statements in accordance with IFRS requires the Company to use judgment in applying its accounting policies and make estimates and assumptions about reported amounts at the date of the financial statements and in the future. The Company’s management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.   Useful lives of property and equipment   Estimates of the useful lives of property and equipment and intangible assets are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence, not electing to exercise renewal options on Leases, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of the property and equipment and intangible assets would increase the recorded expenses and decrease the non-current assets.   Provision for expected credit losses on trade receivables   The provision for expected credit losses on trade receivables are estimated based on historical information, customer concentrations, customer solvency, current economic and geographical trends, and changes in customer payment terms and practices. The Company will calibrate its provision matrix to adjust the historical credit loss experience with forward-looking information. The assessment of the correlation between historical observed default rates, forecast economic conditions and expected credit losses is a significant estimate. The amount of expected credit losses is sensitive to changes in circumstances and of forecast economic conditions. The Company’s historical credit loss experience and forecast of economic conditions may also not be representative of the customer’s actual default in the future.   Estimating the incremental borrowing rate on leases   The Company cannot readily determine the interest rate implicit in leases where it is the lessee. As such, it uses its incremental borrowing rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of comparable value to the right-of-use asset in a similar economic environment. IBR therefore reflects what the Company “would have to pay”, which requires estimation when no observable rates are available or where the applicable rates need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates.   Estimating the fair value of share-based payment transactions   The Company utilizes a Black-Scholes model, or where appropriate, a Monte-Carlo Simulation to estimate the fair value of its share-based payments. In applying these models, management must estimate the expected future volatility of the Company’s estimated share price and makes such assumptions based on a proxy of publicly listed entities under an expectation that historical volatility is representative of the expected future volatility. Additionally, estimates have been made by management, in respect of the performance warrants, regarding the length of the vesting period as well as the number of performance warrants that are likely to vest.   Estimating the fair value of financial instruments   When the Company recognizes a financial instrument, where there is no active market for such an instrument, the Company utilizes alternative valuation methods. The Company utilizes inputs from observable markets to the extent that an appropriate market can be identified, but when there is a lack of such a market, the Company applies judgment to determine a fair value. Such judgments require those such as risk and volatility, of which changes in such assumptions may impact the fair value of the financial instrument.   Other significant judgments   The preparation of these financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s financial statements include:     ● The assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to significant uncertainty;     ● The determination of the lease term of contracts with renewal and termination options;     ● Determination of the extent to which it is probable that future taxable income will be available to allow all or part of the temporary differences and net operating losses to be utilized;     ● Whether there are indicators of impairment of the Company’s long-lived assets, including its intangible assets; and     ● Development costs do not meet the conditions for capitalization in accordance with IAS 38 and therefore all research and development costs have been expensed as incurred.

v3.24.3

Trade and Other Receivables	6 Months Ended
	Jun. 30, 2024
Trade and Other Receivables [Abstract]
TRADE AND OTHER RECEIVABLES	4. TRADE AND OTHER RECEIVABLES       June 30,     December 31,       2024     2023   Trade receivables   $ 172,047     $ 121,735   Less: allowance for doubtful accounts     (32,633 )     (28,180 ) Trade receivables, net   $ 139,414     $ 93,555     For the six months ended June 30, 2024 and 2023, the Company recorded allowance for doubtful accounts of $5,361 and $(17,065) for trade receivables. For the six months ended June 30, 2024, the Company wrote off of trade receivable of $10,795.

v3.24.3

Inventories	6 Months Ended
	Jun. 30, 2024
Inventories [Abstract]
INVENTORIES	5. INVENTORIES       June 30,     December 31,       2024     2023   Raw materials   $ 373,718     $ 430,004   Finished goods     178,810       240,467         552,528       670,471   Less: Reserve     (31,997 )     (56,833 )     $ 520,531     $ 613,638     For the six months ended June 30, 2024 and 2023, the Company recorded an inventory write down of $67,080 and $0 due to expiration of raw materials.

v3.24.3

Prepaid and Other Current Assets	6 Months Ended
	Jun. 30, 2024
Prepaid and Other Current Assets [Abstract]
PREPAID AND OTHER CURRENT ASSETS	6. PREPAID AND OTHER CURRENT ASSETS       June 30,     December 31,       2024     2023   Prepaid insurance   $ 220,668     $ 478,116   Other prepaid expense     204,198       327,538   Security deposit     131,073       135,061   VAT receivable     195,950       260,955   Other assets     105       108       $ 751,994     $ 1,201,778     For the six months ended June 30, 2023, the Company recorded a valuation reserve of $53,295 for VAT receivables.

v3.24.3

Property and Equipment	6 Months Ended
	Jun. 30, 2024
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	7. PROPERTY AND EQUIPMENT   Property and equipment and the changes in property, equipment and accumulated depreciation for the six months ended June 30, 2024 are provided as follows:       Laboratory equipment     Office equipment     Construction in progress     Total   Cost                         Balance at December 31, 2023   $ 1,494,732     $ 418,680     $ 59,929     $ 1,973,341   Additions     50,861       69,799       -       120,660   Disposal/reclasses     (22,751 )     (11,399 )     (9,346 )     (43,496 ) Effects of currency translation     (44,276 )     (12,644 )     (1,725 )     (58,645 ) Balance at June 30, 2024   $ 1,478,566     $ 464,436     $ 48,858     $ 1,991,860                                     Accumulated depreciation                                 Balance at December 31, 2023   $ 184,149     $ 86,875     $ -     $ 271,024   Depreciation     70,743       33,281       -       104,024   Disposal/reclasses     -       -       -       -   Effects of currency translation     (5,837 )     (2,724 )     -       (8,561 ) Balance at June 30, 2024   $ 249,055     $ 117,432     $ -     $ 366,487   Net book value at Dec 31, 2023   $ 1,310,583     $ 331,805     $ 59,929     $ 1,702,317   Net book value at June 30, 2024   $ 1,229,511     $ 347,004     $ 48,858     $ 1,625,373     For the six months ended June 30, 2024 and 2023, the Company recorded depreciation of $104,024 and $112,933, and loss on disposal of property and equipment including in depreciation and amortization expense of $43,496 and $0, respectively   During 2023, we began the expansion of our clinical laboratory in our headquarters facility. Expenditures related to that lab expansion are included in construction in progress. During the first six months of 2024, the Company did not incur significant costs related to the development of the new lab space as it was awaiting local government approvals on the work done to date.   As of June 30, 2024 and December 31, 2023, management assessed that there were no events or changes in circumstances that would require impairment testing of its fixed assets.

v3.24.3

Intangible Asset	6 Months Ended
	Jun. 30, 2024
Intangible Assets [Abstract]
INTANGIBLE ASSET	8. INTANGIBLE ASSET   Our flagship product is ColoAlert, a colorectal cancer (“CRC”) screening test. On January 1, 2019, we entered into an exclusive licensing agreement (the “Licensing Agreement”) with ColoAlert AS to license the intellectual property related to the ColoAlert test.   On February 15, 2023, we entered into an Intellectual Property Asset Purchase Agreement (“IPA”), which superseded the Licensing Agreement. Pursuant to the IPA, we acquired the intellectual property underlying the ColoAlert test. Pursuant to the IPA, we were able to reduce the price paid for the intellectual property to (i) $2 million cash, to be paid out over the next four years, (ii) 300,000 ordinary restricted shares and (iii) a revenue share limited to $1 per test sold for a period of 10 years. The Company recognized an intangible asset from this purchase and assigned a 10-year useful life. The intangible assets were valued: (a) for the portion to be settled in stock of the Company at the value on the day of closing, or $6.85 per share, and (b) for the cash portion, at the present value of the future payments using a 10% discount.   During the six months ended June 30, 2024, the Company paid $300,000 to the seller. The Company recorded amortization of $188,591 and interest expense of $50,858 for the six months ended June 30, 2024. As of June 30, 2024 and December 31, 2023, the liability for remaining required payments of $875,564 and $1,115,816 is recorded as intellectual property acquisition liability – related party (current and non-current) on the Statement of Financial Position.   In January 2022, the Company licensed the right to a novel set of mRNA biomarkers, including the exclusive license under a patent pending. Upon completion of the Company’s evaluation of those biomarkers it exercised its right to acquire the rights to those biomarkers including the rights under the patent pending on February 15, 2023. The Company plans to use several of these biomarkers in its next generation product. Pursuant to the technology assignment agreement with SOCPRA Sciences Sante et Humaines S.E.C., operating under the name Transfertech Sherbrooke (“Sherbrooke”), the Company will owe Sherbrooke a royalty payment of 2% of net sales for any product sold that incorporates the biomarkers.   The activity in the Intangible Asset account for the six months ended June 30, 2024 is as follows:       Intangible asset   Net book amount at December 31, 2023   $ 3,394,645   Additions     -   Disposal     -   Amortization     (188,591 ) Net book amount at June 30, 2024   $ 3,206,054     At June 30, 2024, the Company analyzed the recoverability of its intangible assets and determined that an indicator of impairment did not exist. As of June 30, 2024, the Company determined that there had not been negative events or circumstances relating to the recoverability of the intangible assets.

v3.24.3

Leases	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
LEASES	9. LEASES   Right-of-Use Assets   The Company’s leases certain assets under lease agreements.       Office     Laboratory                         Equipment     Equipment     Vehicle     Office     Total   Cost                               Balance at December 31, 2023   $ 28,429     $ 94,062     $ 169,115     $ 1,664,637     $ 1,956,243   Additions     -       37,007       -       63,571       100,578   Effects of currency translation     (839 )     (2,958 )     (4,994 )     (49,468 )     (58,259 ) Balance at June 30, 2024   $ 27,590     $ 128,111     $ 164,121     $ 1,678,740     $ 1,998,562                                             Accumulated amortization                                         Balance at December 31, 2023   $ 17,927     $ 37,485     $ 74,724     $ 493,937     $ 624,073   Amortization     5,099       9,912       26,061       119,728       160,800   Effects of currency translation     (554 )     (1,156 )     (2,334 )     (15,167 )     (19,211 ) Balance at June 30, 2024   $ 22,472     $ 46,241     $ 98,451     $ 598,498     $ 765,662   Net book value                                         December 31, 2023   $ 10,502     $ 56,577     $ 94,391     $ 1,170,700     $ 1,332,170   June 30, 2024   $ 5,118     $ 81,870     $ 65,670     $ 1,080,242     $ 1,232,900     As of June 30, 2024 and December 31, 2023, management assessed that there were no events or changes in circumstances that would require impairment testing of our right of use assets.   The carrying amount of the right-of-use assets is amortized on a straight-line basis over the life of the leases, which at June 30, 2024, had an average expected life of 4.50 years.   Lease Liabilities   The Company’s lease liabilities consist of office and laboratory equipment and office space. The present value of future lease payments were measured using an weighted average incremental borrowing rate of 9.80% per annum as of June 30, 2024.       Total   Balance at December 31, 2023   $ 1,454,186   Additions     100,578   Interest expenses(*)     67,876   Lease payments (*)     (214,180 ) Effects of currency translation     (42,724 ) Balance at June 30, 2024   $ 1,365,736     Lease liabilities   June 30, 2024   Current portion   $ 319,573   Long-term portion     1,046,163   Total lease liabilities   $ 1,365,736     (*) Payment of lease obligation under financing activities is $146,304, excluding interest expense.

v3.24.3

Accounts Payable and Accrued Liabilities	6 Months Ended
	Jun. 30, 2024
Accounts Payable and Accrued Expenses [Abstarct]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	10. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES       June 30,     December 31,       2024     2023   Accounts payable   $ 1,653,002     $ 2,326,439   Accrued expenses     1,130,423       725,208   Payroll liabilities     120,448       132,734       $ 2,903,873     $ 3,184,381

v3.24.3

Convertible Debt – Related Party	6 Months Ended
	Jun. 30, 2024
Convertible Debt – Related Party [Abstract]
CONVERTIBLE DEBT – RELATED PARTY	11. CONVERTIBLE DEBT – RELATED PARTY   During the years ended December 31, 2019 and 2020, the Company entered into loan agreements with related parties totaling EUR417,133 (approximately $467,154) (the “2019 and 2020 Convertible Loans”). The 2019 and 2020 Convertible Loans bear interest at 3.5% and have a maturity date of September 30, 2022. One of the convertible loans has not been converted and is payable on demand (balance of EUR30,000 ($33,118) as of December 31, 2023) and June 30, 2024 ($32,205). While the 2019 and 2020 Convertible Loans are outstanding, the lenders are entitled to 0.5% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lenders do not partake in the Company’s losses. At maturity, the 2019 and 2020 Convertible Loans are convertible into ordinary shares of the Company at EUR1 per share.   The 2019 and 2020 Convertible Loans were determined to be a financial instrument comprising an equity classified conversion feature with a host debt component. On initial recognition, the Company used the residual value method to allocate the principal amount of the 2019 and 2020 Convertible Loans between the two components. The host debt component was valued first, based on similar debt securities without an embedded conversion feature and the residual was allocated to the equity-classified conversion feature. The Company recognized debt discounts totaling EUR13,064 on issuance of the 2019 and 2020 Convertible Loans.   A continuity of the Company’s Convertible Debt – Related Party is as follows:       2019 and 2020 Convertible Loans   Balance, December 31, 2023   $ 33,118   Effects of currency translation     (978 ) Balance, June 30, 2024   $ 32,140

v3.24.3

Convertible Debt	6 Months Ended
	Jun. 30, 2024
Convertible Debt [Abstract]
CONVERTIBLE DEBT	12. CONVERTIBLE DEBT   The Company’s Convertible Debt includes a Convertible Loan entered into in November 2017 and a series of Convertible Promissory Notes entered into during 2023 and 2024. Both the Loan and Notes are further detailed as follows:   Convertible Loan   In November 2017, the Company entered into loan agreements with two former shareholders of the Company for loans totaling EUR80,278 (approximately $92,007) (the “2017 Convertible Loans”). As of June 30, 2024, one of the 2017 Convertible Loans is outstanding and is payable on demand, with a balance of EUR40,139 ($43,003). The remaining loan is convertible at the option of the lender to shares totaling 4.25% of the Company’s common shares outstanding at the time of conversion. The loan is non-interest bearing, are unsecured and are due on demand.   A continuity of the Company’s Convertible loan is as follows:       2017 Convertible Loans   Balance, December 31, 2023   $ 44,310   Effects of currency translation     (1,307 ) Balance, June 30, 2024   $ 43,003     Convertible Promissory Notes   On June 28, 2023, we entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd. (“Holder”). Pursuant to the PPA, we may request that the Holder purchase from us up to $50,000,000 (the “Commitment Amount”) of promissory notes (each, a “Promissory Note”). The Holder will purchase each Promissory Note at 92% of the principal amount of that Promissory Note. On June 28, 2023, we sold the Holder a Promissory Note (the “Initial Promissory Note”) in the principal amount of $5,500,000 and received $5,060,000, net of discount. The Holder is not obligated to purchase any additional Promissory Notes from us under the PPA. On September 26, 2023, the Company issued a second Promissory Note of $5,500,000 and received $5,060,000, net of discount (the “Second Promissory Note”).   On April 18, 2024, we sold the Holder a Promissory Note (the “Third Promissory Note”) in the principal amount of $3,300,000 and received $2,970,000, net of discount and paid legal fee of $25,000.   Each Promissory Note matures one year from the date of its issuance. The Promissory Notes do not carry any interest, except if there is an event of default in which case the interest is 15% per annum. We may prepay a Promissory Note with at an 8% premium with advance written notice ranging between five business days and thirty calendar days prior to such prepayment, depending on the market price of our ordinary shares at the time of the notice.   The Promissory Notes are convertible at the Holder’s discretion into our ordinary shares at a conversion price (the “Conversion Price”) equal to the lower of (a) (I) $4.9986 in respect of the Initial Promissory Note, (II) $3.5424 in respect of the Second Promissory Note, and (III) with respect to each subsequent Promissory Note, if any, 110% of the volume weighted average price (“VWAP”) of our ordinary shares on the trading day immediately preceding the issuance of such Promissory Note (the “Fixed Price”) or (b) 92% of the average of the two lowest daily VWAPs of the shares during the eight trading days immediately prior to such conversion. In no event, however, shall the conversion price be less than a floor price of $2.00, as may be adjusted for stock splits and other similar transactions (the “Floor Price”).   Under the Promissory Notes, a “Trigger Event” occurs if the trading price of an ordinary share is lower than the applicable Floor Price for any five of seven consecutive trading days. Within five trading days of a Trigger Event, we must make a monthly cash payment to the Holder in connection with the Promissory Notes (the “Monthly Payment”) equal to the lesser of (i) $550,000, plus an 8% redemption premium on any principal being repaid plus any accrued and unpaid interest and (ii) all principal outstanding under all outstanding Promissory Notes, plus an 8% redemption premium on any principal being repaid plus any accrued and unpaid interest. Thereafter, we must pay the Holder a Monthly Payment every 30 calendar days after the due date of the initial Monthly Payment; provided that our monthly obligation hereunder will end with respect to a particular Trigger Event if (i) the daily VWAP of the ordinary shares for seven consecutive trading days immediately prior to the due date of the next Monthly Payment is 10% or greater than the Floor Price or (ii) we reduce the Floor Price for all outstanding Promissory Notes by 50%, unless a new Trigger Event occurs.   In connection with the execution of the PPA, we agreed to pay a commitment fee of $250,000. Such commitment fee was paid on the date of the PPA (June 28, 2023) in the form of 54,428 ordinary shares, which was derived using a per ordinary share price equal to the average of the daily VWAPs of the Ordinary Shares during the three trading days prior to the PPA.   The Company elected to account for the Promissory Notes at fair value through FVTPL. Management believes that the fair value option appropriately reflects the underlying economics of the Promissory Notes. Under the fair value election in IFRS 9, changes in fair value of the Promissory Notes, will be reported in the Consolidated Statements of Operations, under change in fair value of debt instrument, in each reporting period subsequent to the issuance of the Promissory Note. The Initial Promissory Note had a face value of $5,500,000 and had an original issue discount of $440,000. The Company recorded the Initial Promissory Note at its fair value of $5,060,000, which was also the cash received, the Second Promissory Note at its fair value of $5,008,000 and the Third Promissory Note at its fair value of $2,822,000.   In November 2023, there was both a Trigger Event and default under the PPA and Promissory Notes. As a result, beginning in November 2023 the Company is incurring default interest of 15% per annum and is required to amortize the Notes with monthly cash payments. During November and December 2023, the Company paid $1,100,000 in principal under the notes and associated 8% premium and 15% default interest. During the period from January 1, 2024 to March 26, 2024, we continued to make payments as scheduled in a combination of cash and ordinary shares. Beginning in April subject to a mutual agreement between the holder of the Notes and the Company, we began issuing share notices under the PPA. As a result, we issued 4,421,093 ordinary shares during the six months ended June 30, 2024, which resulted in principal reductions of $2.6 million, interest of interest of $0.6 million and net proceeds to the Company of $0.5 million. Pursuant to the mutual agreement of the holder of the Notes and the Company is continuing to repay the outstanding Notes through share issuances, past the original date of maturity, without penalty.   During the six months ended June 30, 2024, the Company repaid principal amounts of the Second Promissory Note of $787,633 and accrued interest of $70,782.   During the six months ended June 30, 2024, principal amounts of the Second Promissory Note of $1,770,577 and accrued interest of $383,980 were converted into 3,366,093 ordinary shares, at conversion prices ranging from $0.18 to $0.95.   For the six months ended June 30, 2024 and 2023, the Company recorded a change in fair value of $528,210 and $45,000, resulting in a balance of $5,799,000 and $4,859,000 as of June 30, 2024 and December 31, 2023, respectively.   Changes in the balance of the convertible notes are as follows:             Carrying             Amount at       Face Value     Fair value   Balance at December 31, 2023   $ 6,400,000     $ 4,859,000   Issuance of convertible promissory notes     3,300,000       2,970,000   Repayments of convertible promissory notes     (787,633 )     (787,633 ) Conversion of notes with ordinary shares     (1,770,577 )     (1,770,577 ) Change in fair value of convertible promissory notes     -       528,210   Balance at June 30, 2024   $ 7,141,790     $ 5,799,000     We classified this fair value as a Level 3 fair value measurement and used a fair value pricing model to calculate the fair value for the six months ended June 30, 2024. Key inputs for the fair value model are summarized below.   A summary of the Company’s significant inputs into the fair value of the Promissory Notes is as follows:         June 30,         2024   Stock price   $ 0.40 - 0.90   Expected life in years     0.50 - 0.92   Risk free rate     5.25% - 5.56% Expected volatility     105% - 130%

v3.24.3

Silent Partnerships	6 Months Ended
	Jun. 30, 2024
Silent Partnerships [Abstract]
SILENT PARTNERSHIPS	13. SILENT PARTNERSHIPS   Certain of the Silent Partnership agreements are with a German based bank, which also owns ordinary shares of the Company. Those debts are classified as “related party” in the statement of financial position (See Note 15). A continuity of the Company’s silent partnerships is as follows:       3% SPAs     3.5% SPAs     8.5% SPAs     Total   Balance, December 31, 2023   $ 596,257     $ 48,695     $ 385,214     $ 1,030,166   Accretion     22,367       1,788       6,347       30,502   Effects of currency translation     (17,716 )     (1,447 )     (11,407 )     (30,570 ) Balance, June 30, 2024   $ 600,908     $ 49,036     $ 380,154     $ 1,030,098

v3.24.3

Equity	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
EQUITY	14. EQUITY   Ordinary shares   As of December 31, 2023, the Company had 45 million ordinary shares authorized. On May 31, 2024 the shareholders of the Company approved an increase of authorized ordinary share of up to 90 million, with an approved increase to 225 million ordinary shares at anytime ordinary shares outstanding is to exceed 90 million. Holders of ordinary shares are entitled to dividends as declared from time to time and are entitled to one vote per share at general meetings of the Company. The par value of share capital is EUR0.01 per share.   During the six months ended June 30, 2024, the Company issued ordinary shares as follows:     ● 1,055,000 ordinary shares issued for $515,262; and     ● 3,366,093 ordinary shares issued for conversion of debt of $2,154,557.    During the six months ended June 30, 2023   Controlled Equity Offering   In December 2022, the Company entered into a Controlled Equity Offering, known as an “ATM” facility. Pursuant to the ATM, the Company at its discretion and subject to an effective registration statement with the U.S. Securities and Exchange Commission, may sell through its agent ordinary shares at market prices, for a fee of 3%. During the year ended December 31, 2023 the Company issued 307,365 ordinary shares pursuant to the ATM for net proceeds of $1,893,196, at an average price of $6.16 per share. No shares were issued in the six months ended June 30, 2024 under the ATM.   In addition, the Company issued ordinary shares as follows:     ● 34,500 ordinary shares issued for services rendered which were valued at $177,690     ● 305,771 ordinary shares issued for cashless exercise of warrants     ● 54,428 ordinary shares issued for a commitment fee on a convertible promissory note valued at $250,000     ● 300,000 ordinary shares issued for acquisition of intangible assets valued at $2,055,000   Warrants   During the year ended December 31, 2021, in conjunction with private sales of units, which included ordinary shares and warrants, the Company issued 3,755,000 warrants and issued 161,000 underwriter warrants with its IPO, cumulatively valued at $754,286, which was recorded to Reserve in the Consolidated Statement of Financial Position. The warrants were valued using the Black-Scholes pricing model. The Black-Scholes model requires six basic data inputs, which were as follows: the exercise or strike price ($3.00), time to expiration (2 to 5 years), the risk-free interest rate (0.16% to 1.08%), the current stock price at time of issuance ($0.283 to $1.602), the estimated volatility of the stock price in the future (75% to 95%), and the dividend rate (0%). Changes to these inputs could produce a significantly higher or lower fair value measurement. Unexercised warrants were to expire in November 2023. On September 8, 2023 the Board of Directors approved an amendment to the outstanding warrant agreements, which all remaining warrant holders accepted. The amendment extended the remaining life of the warrants to November 9, 2024 and removed the option for cashless exercise. No other terms were changed.   On November 13, 2023, the Company issued 4,166,667 warrants, as a part of the Unit offering, valued using the residual method and an assigned value of $0. The Warrants were exercisable immediately on the date of issuance until the fifth anniversary of the issuance date at a price of $1.20 per share.   A summary of activity during the six months ended June 30, 2024 is as follows:       Warrant     Weighted-Average     Weighted-Average       Outstanding     Exercise Price     Life (years)   Balance as of December 31, 2023     6,597,500     $ 1.86       3.39   Grants     -       -       -   Exercised     -       -       -   Expired     -       -       -   Balance as of June 30, 2024     6,597,500     $ 1.86       2.90     As of June 30, 2024, all outstanding warrants are exercisable and the intrinsic value of the warrants is $0.   Stock options   In 2021, our shareholders adopted our 2021 Omnibus Incentive Plan (the “2021 Plan”). Under the 2021 Plan, we are authorized to issue equity incentives in the form of incentive stock options, non-statutory stock options, restricted shares, restricted share units, share appreciation rights, performance units or performance shares under separate award agreements. Under the 2021 Plan, the aggregate number of shares underlying awards that we could issue cannot exceed 2,300,000 ordinary shares.   In 2022, our shareholders adopted our 2022 Omnibus Incentive Plan (the (“2022 Plan”). Under the 2022 Plan, we are authorized to issue equity incentives in the form of incentive stock options, non-statutory stock options, restricted shares, restricted share units, share appreciation rights, performance units or performance shares under separate award agreements. Under the 2022 Plan, the aggregate number of shares underlying awards that we could issue cannot exceed 500,000 ordinary shares. In 2023, we amended the 2022 Plan to increase the aggregate number of shares underlying awards that we could issue to 875,000 ordinary shares.   During the six months ended June 30, 2023, the Company granted 312,500 stock options valued at $1,072,612. Stock options with time-based vesting were valued using the Black-Scholes pricing model.   During the six months ended June 30, 2024 and 2023, the Company recorded share-based compensation of $1,028,383 and $1,668,673. Forfeitures are estimated at the time of grant and adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates.   For the six months ended June 30, 2023, the estimated fair values of the stock options are as follows:         June 30,         2023   Exercise price   $ 4.78 - 7.02   Expected term     5.25 - 7.00 years   Expected average volatility     70% - 76%   Expected dividend yield     -   Risk-free interest rate     3.48% - 4.27%     A summary of activity during the six months ended June 30, 2024 follows:       Stock options     Weighted-Average     Weighted-Average       Outstanding     Exercise Price     Life (years)   Balance as of December 31, 2023     2,727,150     $ 6.89       8.44   Grants     -       -       -   Exercised     -       -       -   Forfeited/Cancelled     -       -       -   Expiry     -       -       -   Balance as of June 30, 2024     2,727,150     $ 6.89       7.89                             Exercisable as of June 30, 2024     1,958,775     $ 6.48       7.57   Expect to vest     768,375     $ 7.76       2.22     A summary of activity during the six months ended June 30, 2023 follows:       Stock options     Weighted-Average     Weighted-Average       Outstanding     Exercise Price     Life (years)   Balance as of December 31, 2022     2,394,150     $ 7.18       9.11   Grants     312,500       5.06       10.00   Exercised     -       -       -   Forfeited     (27,592 )     6.88       -   Expired     -       -       -   Balance as of June 30, 2023     2,679,058     $ 6.97       8.80                             Exercisable as of June 30, 2023     1,567,950     $ 5.95       8.40     As of June 30, 2024, the intrinsic value of the stock options is $0.

v3.24.3

Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	15. RELATED PARTY TRANSACTIONS   Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company’s Board, its Chief Executive Officer, Chief Financial Officer, Chief Commercial Officer, Chief Business Officer and Chief Scientific Officer. The remuneration of directors and key management personnel during the six months ended June 30, 2024 and 2023 was as follows:       Six months ended       June 30,       2024     2023   Salaries and benefits   $ 552,926     $ 921,492     As of June 30, 2024 and December 31, 2023, the Company recorded accounts payable – related party of $37,088 and $32,702, and accrued management salaries of $358,398 and $267,234, respectively.   Remuneration paid to related parties other than key personnel during the six months ended June 30, 2024 and 2023 was as follows:       Six months ended       June 30,       2024     2023   Salaries and benefits   $ 21,292     $ 14,956     During the six months ended June 30, 2024 and 2023, we recorded expenses of $186,601 and $52,264, respectively, for the cost of royalties and other associated costs owed to ColoAlert AS (and its successor, Uni Targeting Research AS, collectively “ColoAlert AS”), the company from which we exclusively licensed the ColoAlert product. A non-executive director of the Company is also an owner of ColoAlert AS. During the six months ended June 30, 2024 and 2023, we paid ColoAlert AS $155,450 and $173,844, respectively. As of June 30, 2024 and December 31, 2023, we had liabilities recorded for unpaid costs to ColoAlert AS of $31,151 and $0, respectively, recorded as Accounts payable – related party.   Silent partnerships   As at June 30, 2024, EUR 200,000 (approximately $214,264) with a carrying value of $267,206 of the 8.5% SPAs were owing to major shareholders of the Company. EUR 200,000 of the loan is due on December 31, 2025.    As at December 31, 2023, EUR 200,000 (approximately $220,784) with a carrying value of $271,354 of the 8.5% SPAs were owing to major shareholders of the Company. EUR 200,000 of the loan is due on December 31, 2025.    During the six months ended June 30, 2024 and 2023, the Company incurred interest expense of $9,716 and $16,664 on balances owing to related parties, respectively.   During the six months ended June 30, 2024 and 2023, the Company incurred accretion expense of $3,884 and $6,807 on balances owing to related parties, respectively.

v3.24.3

Government Grants	6 Months Ended
	Jun. 30, 2024
Government Grants [Abstract]
GOVERNMENT GRANTS	16. GOVERNMENT GRANTS   The Company receives government grants related to its research and development activities. The amount of government grants received during the six months ended June 30, 2024 and 2023 and recognized in Other Income were as follows:       Six months ended       June 30,   Research and Development Projects   2024     2023   Multi-marker test for the early detection of pancreatic cancer   $ 46,087     $ 28,117     As of June 30, 2024 and December 31, 2023, the grants for rapid detection of antibody-based pathogens and a multi-marker test for the early detection of pancreatic cancer had remaining grant balances of approximately $46,010 and $6,604, respectively.

v3.24.3

Financial Instrument Risk Management	6 Months Ended
	Jun. 30, 2024
Financial Instrument Risk Management [Abstract]
FINANCIAL INSTRUMENT RISK MANAGEMENT	17. FINANCIAL INSTRUMENT RISK MANAGEMENT   Basis of Fair Value   Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:   ● Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities;   ● Level 2 — Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and   ● Level 3 — Inputs that are not based on observable market data.   The Company’s financial instruments consist of cash, trade and other receivables, accounts payable and accrued liabilities, lease liabilities, convertible debentures, and loans payable. With the exception of convertible debentures and loans payable, the carrying value of the Company’s financial instruments approximate their fair values due to their short-term maturities. The fair value of convertible debentures and notes payable approximate their carrying value, excluding discounts, due to minimal changes in interest rates and the Company’s credit risk since issuance of the instruments.   The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures.   Credit Risk   The Company’s principal financial assets are cash and trade receivables. The Company’s credit risk is primarily concentrated in its cash which is held with institutions with a high credit worthiness. Management believes that the Company is not exposed to any significant credit risk with respect to its cash.   The Company mitigates its credit risk on receivables by actively managing and monitoring its receivables. The Company has been determined that no credit loss provision is required, as all amounts outstanding are considered collectible. During the six months ended June 30, 2024, the Company incurred $16,090 (related to Trade receivable and VAT receivable) in bad debt expense (2023 - $53,295). The Company mitigates credit risk by evaluating the creditworthiness of customers prior to conducting business with them and monitoring its exposure for credit losses with existing customers.   Liquidity Risk   Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company’s normal operating requirements on an ongoing basis. As at June 30, 2024 and December 31, 2023, the Company had an unrestricted cash balance of $977,764 and $7,070,925, and convertible promissory notes of $5,799,000 and $4,859,000, respectively. The Company is selling shares pursuant to its PPA, and the proceeds are being using to make principal and interest payments to the lender.   Historically, the Company’s primary source of funding has been the sale of ordinary shares and borrowings. The Company’s access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.   The following is an analysis of the contractual maturities of the Company’s financial liabilities as at June 30, 2024 and December 31, 2023:   At June 30, 2024:       Within     More than     More than       one year     one year     five years   Accounts payable and accrued liabilities   $ 2,903,873     $ -     $ -   Accounts payable - related party     426,637       -       -   Deferred revenue     116,679       -       -   Convertible promissory note to be settled with ordinary shares     5,799,000       -       -   Convertible loans     75,143       -       -   Loans payable     -       -       -   Silent partnerships     49,036       981,062       -   Lease liabilities     319,573       688,672       357,491   Intellectual property acquisition liability - related party     324,003       551,561       -       $ 10,013,944     $ 2,221,295     $ 357,491     At December 31, 2023:       Within     More than     More than       one year     one year     five years   Accounts payable and accrued liabilities   $ 3,184,381     $ -     $ -   Accounts payable and accrued expenses– related party     299,936       -       -   Deferred revenue     138,889       -       -   Convertible promissory note     4,859,000       -       -   Convertible loans     77,428       -       -   Silent partnerships     -       1,030,166       -   Lease liabilities     288,463       812,910       352,813   Intellectual property acquisition liability - related party     388,839       726,977       -       $ 9,236,936     $ 2,570,053     $ 352,813     Foreign Exchange Risk   Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. As the Company operates in Germany it holds a portion of its cash balances in Euro to approximate between three to twelve months estimated operating needs. The remainder of the Company’s cash is held in U.S. Dollars, the Company’s reporting currency, which is also the currency of the Company’s largest cash outlays over the next twenty-four months.   Interest Rate Risk   Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as its financial liabilities carry interest at fixed rates.   Capital Management   The Company aims to manage its capital resources to ensure financial strength and to maximize its financial flexibility by maintaining strong liquidity and by utilizing alternative sources of capital including equity, debt and bank loans or lines of credit to fund continued growth. The Company sets the amount of capital in proportion to risk and based on the availability of funding sources. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. As an early-stage growth company, the sale of ordinary shares has been the primary source of capital to date. Additional debt and/or equity financing may be pursued in future as deemed appropriate to balance debt and equity. To maintain or adjust the capital structure, the Company may issue new shares, take on additional debt or sell assets to reduce debt.

v3.24.3

Concentrations	6 Months Ended
	Jun. 30, 2024
Concentrations [Abstract]
CONCENTRATIONS	18. CONCENTRATIONS   Major customers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. For the six months ended June 30, 2024 and 2023, the Company had revenue from one customer that accounted for approximately 43% and 18% of revenue, respectively.

v3.24.3

Operating Expenses	6 Months Ended
	Jun. 30, 2024
Operating Expenses [Abstract]
OPERATING EXPENSES	19. OPERATING EXPENSES   For the six months ended June 30, 2024 and 2023, operating expenses consisted of the following:        Six months ended       June 30,   Sales and marketing   2024     2023   Salaries and Benefits   $ 745,716     $ 615,147   Professional and consulting fees     655,810       1,143,077   Office expenses     25,360       -   Travel and entertainment     46,832       57,943   Depreciation and amortization     2,336       -   Marketing and advertising     885,051       2,176,808       $ 2,361,105     $ 3,992,975         Six months ended       June 30,   Research and development   2024     2023   Salaries and benefits   $ 2,055,067     $ 2,028,880   Professional fees     299,044       665,894   Clinical studies     322,000       2,162,000   Office expenses     87,885       193,936   Travel and entertainment     59,123       100,383   Depreciation and amortization     284,591       210,875   Materials for clinical studies     134,912       119,261       $ 3,242,622     $ 5,481,229         Six months ended       June 30,   General and administrative   2024     2023   Salaries and benefits   $ 1,524,397     $ 1,271,181   Employee stock option expense     1,028,383       1,668,673   Professional and consulting fees     1,038,126       1,146,792   Office expenses     411,367       345,752   Insurance     261,473       478,149   Travel and entertainment     48,872       69,924   Depreciation and amortization     210,021       246,710       $ 4,522,639     $ 5,227,181

v3.24.3

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstarct]
SUBSEQUENT EVENTS	20. SUBSEQUENT EVENTS   The Company has performed its review of subsequent events through October 17, 2024. Subsequent to June 30, 2024:   The Company issued 31,353,911 ordinary shares pursuant to its PPA. As a result, the Company received proceeds of $3,787,312 and recorded a reduction of principal on its convertible notes of $5,284,550.   During July 2024 and October 2024, the Company restructured its operations to focus on its ColoAlert business in Europe, the development of its next generation product, and planning for the Early Detect 2 clinical study in the U.S. in 2025. In line with that focus, the Company implemented cost reduction efforts which included the reduction of its operating costs, including the reduction of personnel by 65%, reduction of external consulting costs, and the sale/closure of its European Oncology Lab (“EOL”) business in St. Ingbert, Germany. The sale of the EOL business included a payment to the Company of €35,000. Additionally, the Company amended the employment contracts of its CEO and CFO, reducing the salaries of those officers to 60% and 50% of their original salaries, respectively, effective November 1, 2024.   The Company issued 1,200,000 ordinary shares to a consultant related to an annual agreement.   On October 8, 2024, we issued a fourth promissory note under our PPA in the original principal amount of $1,500,000 with a 10% original issue discount. This note matures one year from the date of its issuance. The note carries any interest at a rate of 7% per annum, except if there is an event of default in which case the interest will increase to 15% per annum. We may prepay the note with at a 5% premium with advance written notice ranging between five business days and thirty calendar days prior to such prepayment, depending on the market price of our ordinary shares. The note is convertible at holder’s discretion into our ordinary shares at a fixed conversion price equal to the lower of either $0.25 per Ordinary Share or 92% of the average of the two lowest daily volume weighted average prices during the eight (8) consecutive trading days immediately preceding a conversion.

v3.24.3

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Inventories	Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on a weighted average cost and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Expenditures that extend the life of the asset are capitalized and depreciated. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Construction in progress is not depreciated until ready for use. Management evaluates the useful lives and method of depreciation at least annually and accounts for any changes to the useful life or method prospectively. Maintenance and repairs are charged to expense as incurred; cost of major additions and betterments are capitalized. The estimated useful lives are: Laboratory equipment   5 – 10 years Office equipment   3 – 10 years
Impairment of Non-Financial Assets	Impairment of Non-Financial Assets The Company performs impairment tests on its long-lived assets, including property and equipment when new events or circumstances occur, or when new information becomes available relating to their recoverability. When the recoverable amount of each separately identifiable asset or cash generating unit (“CGU”) is less than its carrying value, the asset or CGU’s assets are written down to their recoverable amount with the impairment loss charged against profit or loss. A reversal of the impairment loss in a subsequent period will be charged against profit or loss if there is a significant reversal of the circumstances that caused the original impairment. The impairment will be reversed up to the amount of depreciated carrying value that would have otherwise occurred if the impairment loss had not occurred. The CGU’s recoverable amount is evaluated using fair value less costs to sell calculations. In calculating the recoverable amount, the Company utilizes discounted cash flow techniques to determine fair value when it is not possible to determine fair value from active markets or a written offer to purchase. Management calculates the discounted cash flows based upon its best estimate of a number of economic, operating, engineering, environmental, political and social assumptions. Any changes in the assumptions due to changing circumstances may affect the calculation of the recoverable amount. There was no impairment recognized in the consolidated financial statements for the year ended December 31, 2023 or the six months ended June 30, 2024.
Leases	Leases The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration, the Company has the right to obtain substantially all of the economic benefits from the use of the asset through the specified period, and the Company has the right to direct the use of the specified assets, which involves the right to make the decisions that are most relevant to its use. The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets, which are recognized in profit or loss as the expense is incurred.   At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. Lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. Lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the period in which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the rate implicit in the lease, or if not readily determinable, its incremental borrowing rate (“IBR”). After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset. Upon a remeasurement of a lease liability, the Company records a proportionate adjustment to the corresponding right-of-use asset. If the remeasurement results in a reduction of the right-of-use asset to nil, the difference is recorded in the statements of profit or loss in the period of occurrence. The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated amortization and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are amortized on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.
Revenue Recognition	Revenue Recognition The Company’s revenue is primarily derived through providing genetic diagnostic tests to customers. The Company recognizes revenue in accordance with IFRS 15–- “Revenue from Contracts with Customers”. In accordance with IFRS 15, revenue is recognized upon the satisfaction of performance obligations. Performance obligations are satisfied at the point at which control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive for those goods and services. The Company sells its genetic diagnostic testing kits to both laboratory partners and directly to patients who are the end users of the product. Upon the delivery of our products to laboratory partners the Company has completed its performance obligations and as such revenue is recorded upon delivery. Sales to patients, or end users, where samples are sent to our diagnostic lab for testing and evaluation, are recognized when they are delivered to the end user, returned to our laboratory, and testing results have been delivered. Revenue from these sales is deferred on our Statement of Financial Position until recognition. Revenue is recognised from the sale of testing kits.
Cost of revenue	Cost of revenue Cost of revenue consists of patient test kits and laboratory kits sold to laboratory partners and patients. In the case of test performed in our diagnostic laboratory cost of revenue also includes the labor and overhead related to the performance of those tests.
Research and Development	Research and Development Expenditure on research activities, undertaken with the prospect of gaining new technical knowledge and understanding, is recognized in profit or loss as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labor, overhead costs that are directly attributable to preparing the asset for its intended use, and borrowing costs on qualifying assets. Other development expenditures are recognized in profit or loss as incurred.   Research and development costs incurred subsequent to the acquisition of externally acquired intangible assets and on internally generated intangible assets are accounted for as research and development costs.
Financial Instruments	Financial Instruments a) Classification The Company classifies its financial instruments in the following categories: at fair value through profit and loss (“FVTPL”), at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. b) Measurement Financial assets and liabilities at amortized cost Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. The Company’s financial assets measured at amortized cost are comprised of its cash and trade and other receivables, net. The Company’s financial liabilities measured at amortized cost are comprised of its accounts payable and accrued liabilities, loans payable, loans payable – related party, convertible debt, convertible debt – related parties, silent partnerships, silent partnerships – related party and lease liabilities. Financial assets and liabilities at FVTPL Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the statements of loss and comprehensive loss in the period in which they arise. Debt instruments at FVTOCI These assets are initially measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses associated with changes in fair value are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. The Company does not hold any debt instruments at FVTOCI. Equity instruments at FVTOCI These assets are initially measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses associated with changes in fair value are recognized in OCI and are never reclassified to profit or loss. The Company does not hold any equity instruments at FVTOCI. c) Impairment of financial assets at amortized cost The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the statements of loss and comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.   d) Derecognition Financial assets The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Financial liabilities The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and/or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss.
Convertible Debt	Convertible Debt The Company evaluates at initial recognition of a convertible debt the different components and features of the hybrid instruments and determines whether these elements are equity instruments or embedded derivatives which require bifurcation. In subsequent periods, the liability component is accounted for using (i) the fair value method, or (ii) the effective interest method, based on the expected maturity of the debt. The equity component is not remeasured, while embedded derivatives unless closely related to the host instruments, are recorded at fair value through the Consolidated Statement of Operations unless the convertible debt falls under FVTPL.
Foreign Currency Translation	Foreign Currency Translation The functional currency is determined using the currency of the primary economic environment in which that entity operates. The functional currency, as determined by management, of the Company is the Euro (EUR). Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined. Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in the statement of comprehensive loss in the period in which they arise, except where deferred in equity as a qualifying cash flow or net investment hedge. Exchange differences arising on the translation of non-monetary items are recognized in other comprehensive income to the extent that gains and losses arising on those non-monetary items are also recognized in other comprehensive income. Where the non-monetary gain or loss is recognized in profit or loss, the exchange component is also recognized in profit or loss. The Company’s presentation currency is the US dollar. For presentation purposes, all amounts are translated from the Euro functional currency to the US dollar presentation currency for each period using the exchange rate at the end of each reporting period for the statement of financial position. Revenues and expenses are translated on the basis of average exchange rates during the year. Exchange gains and losses arising from translation to the Company’s presentation currency are recorded as exchange differences on translation to reporting currency, which is included in other comprehensive income (loss).
Income Taxes	Income Taxes Current income tax: Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income. Current income tax relating to items recognized directly in other comprehensive income or equity is recognized in other comprehensive income or equity and not in profit or loss. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. Deferred tax: Deferred tax is recognized on temporary differences at the reporting date arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that future taxable income will be available to allow all or part of the temporary differences to be utilized. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted and are expected to apply by the end of the reporting period. Deferred tax assets and deferred income tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.
Government Grants	Government Grants Government grants are recognized when there is reasonable assurance that the grant will be received and that the Company will comply with the conditions attached to them. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as income in equal amounts over the expected useful life of the related asset. Loans received with better than market terms from government programs are recognized initially at fair value, with the difference between the fair value of the loan based on prevailing market interest rates and the amount received recorded as a gain in the statements of loss and comprehensive loss.
Share-Based Compensation	Share-Based Compensation Our stock option grants may contain time based or market-based vesting provisions. Time based options are expensed on a straight-line basis over the vesting period. Market based options (“MBOs”) are expensed when the related service and market performance conditions are expected to be met, such that the expenses ultimately recognized is based on the number of awards that meet the related service and market performance conditions at the vesting date. The fair value of the stock options is determined on the grant date and is affected by our stock price and other assumptions regarding a number of complex and subjective variables. These variables include our expected stock price volatility over the term of the awards, risk free interest rates, expected dividends, and the expected option exercise term. The Company estimates the fair value of time-based stock options using the Black-Scholes-Merton pricing model. The simplified method is used to estimate the expected term of stock options due to a lack of related historical data regarding exercise, cancellation, and forfeiture. For MBOs, the fair value is estimated using Monte Carlo simulation techniques.   Where an equity-settled award is cancelled, it is treated as if it vested on the date of the cancellation and any expense not yet recognized for the award (being the total expense as calculated at the grant date) is recognized immediately. This includes any awards where vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and designated as a replacement award on the date that it is granted, the cancelled award and new awards are treated as if they were a modification of the original awards.
Loss per Share	Loss per Share Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. For all periods presented, the loss attributable to common shareholders equals the reported loss attributable to owners of the Company. When calculating the diluted earnings (loss) per share, the Company adds to the average number of ordinary shares outstanding, that was used to calculate the basic earnings per share, the weighted average of the number of shares to be issued assuming that all shares that have a potentially dilutive effect would be converted into shares. Potential ordinary shares are only taken into account in cases where their effect is dilutive (reducing the earnings per share or increasing the loss per share). As the Company has recorded net losses from operations in all periods presented, it has excluded stock options and warrants from the diluted Loss per Share calculation as the exercise of such would be anti-dilutive.
Segment Report	Segment Report The Company operates in one operating segment, genetic diagnostic testing.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current year presentation.
Critical Accounting Estimates and Significant Management Judgments	Critical Accounting Estimates and Significant Management Judgments The preparation of financial statements in accordance with IFRS requires the Company to use judgment in applying its accounting policies and make estimates and assumptions about reported amounts at the date of the financial statements and in the future. The Company’s management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Useful lives of property and equipment Estimates of the useful lives of property and equipment and intangible assets are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence, not electing to exercise renewal options on Leases, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of the property and equipment and intangible assets would increase the recorded expenses and decrease the non-current assets. Provision for expected credit losses on trade receivables The provision for expected credit losses on trade receivables are estimated based on historical information, customer concentrations, customer solvency, current economic and geographical trends, and changes in customer payment terms and practices. The Company will calibrate its provision matrix to adjust the historical credit loss experience with forward-looking information. The assessment of the correlation between historical observed default rates, forecast economic conditions and expected credit losses is a significant estimate. The amount of expected credit losses is sensitive to changes in circumstances and of forecast economic conditions. The Company’s historical credit loss experience and forecast of economic conditions may also not be representative of the customer’s actual default in the future.   Estimating the incremental borrowing rate on leases The Company cannot readily determine the interest rate implicit in leases where it is the lessee. As such, it uses its incremental borrowing rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of comparable value to the right-of-use asset in a similar economic environment. IBR therefore reflects what the Company “would have to pay”, which requires estimation when no observable rates are available or where the applicable rates need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates. Estimating the fair value of share-based payment transactions The Company utilizes a Black-Scholes model, or where appropriate, a Monte-Carlo Simulation to estimate the fair value of its share-based payments. In applying these models, management must estimate the expected future volatility of the Company’s estimated share price and makes such assumptions based on a proxy of publicly listed entities under an expectation that historical volatility is representative of the expected future volatility. Additionally, estimates have been made by management, in respect of the performance warrants, regarding the length of the vesting period as well as the number of performance warrants that are likely to vest. Estimating the fair value of financial instruments When the Company recognizes a financial instrument, where there is no active market for such an instrument, the Company utilizes alternative valuation methods. The Company utilizes inputs from observable markets to the extent that an appropriate market can be identified, but when there is a lack of such a market, the Company applies judgment to determine a fair value. Such judgments require those such as risk and volatility, of which changes in such assumptions may impact the fair value of the financial instrument. Other significant judgments The preparation of these financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s financial statements include:   ● The assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to significant uncertainty;   ● The determination of the lease term of contracts with renewal and termination options;   ● Determination of the extent to which it is probable that future taxable income will be available to allow all or part of the temporary differences and net operating losses to be utilized;   ● Whether there are indicators of impairment of the Company’s long-lived assets, including its intangible assets; and   ● Development costs do not meet the conditions for capitalization in accordance with IAS 38 and therefore all research and development costs have been expensed as incurred.

v3.24.3

Summary of Significant Accounting Policies and Use of Estimates and Judgments (Tables)	6 Months Ended
	Jun. 30, 2024
Summary of Significant Accounting Policies and Use of Estimates and Judgments [Abstract]
Schedule of Estimated Useful Lives	The estimated useful lives are: Laboratory equipment   5 – 10 years Office equipment   3 – 10 years

v3.24.3

Trade and Other Receivables (Tables)	6 Months Ended
	Jun. 30, 2024
Trade and Other Receivables [Abstract]
Schedule of Trade and Other Receivables	June 30,     December 31,       2024     2023   Trade receivables   $ 172,047     $ 121,735   Less: allowance for doubtful accounts     (32,633 )     (28,180 ) Trade receivables, net   $ 139,414     $ 93,555

v3.24.3

Inventories (Tables)	6 Months Ended
	Jun. 30, 2024
Inventories [Abstract]
Schedule of Inventories	June 30,     December 31,       2024     2023   Raw materials   $ 373,718     $ 430,004   Finished goods     178,810       240,467         552,528       670,471   Less: Reserve     (31,997 )     (56,833 )     $ 520,531     $ 613,638

v3.24.3

Prepaid and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Prepaid and Other Current Assets [Abstract]
Schedule of Prepaid and Other Current Assets	June 30,     December 31,       2024     2023   Prepaid insurance   $ 220,668     $ 478,116   Other prepaid expense     204,198       327,538   Security deposit     131,073       135,061   VAT receivable     195,950       260,955   Other assets     105       108       $ 751,994     $ 1,201,778

v3.24.3

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Property and Equipment [Abstract]
Schedule of Changes in Property Equipment and Accumulated Depreciation	Property and equipment and the changes in property, equipment and accumulated depreciation for the six months ended June 30, 2024 are provided as follows:     Laboratory equipment     Office equipment     Construction in progress     Total   Cost                         Balance at December 31, 2023   $ 1,494,732     $ 418,680     $ 59,929     $ 1,973,341   Additions     50,861       69,799       -       120,660   Disposal/reclasses     (22,751 )     (11,399 )     (9,346 )     (43,496 ) Effects of currency translation     (44,276 )     (12,644 )     (1,725 )     (58,645 ) Balance at June 30, 2024   $ 1,478,566     $ 464,436     $ 48,858     $ 1,991,860                                     Accumulated depreciation                                 Balance at December 31, 2023   $ 184,149     $ 86,875     $ -     $ 271,024   Depreciation     70,743       33,281       -       104,024   Disposal/reclasses     -       -       -       -   Effects of currency translation     (5,837 )     (2,724 )     -       (8,561 ) Balance at June 30, 2024   $ 249,055     $ 117,432     $ -     $ 366,487   Net book value at Dec 31, 2023   $ 1,310,583     $ 331,805     $ 59,929     $ 1,702,317   Net book value at June 30, 2024   $ 1,229,511     $ 347,004     $ 48,858     $ 1,625,373

v3.24.3

Intangible Asset (Tables)	6 Months Ended
	Jun. 30, 2024
Intangible Assets [Abstract]
Schedule of Intangible Asset Account	The activity in the Intangible Asset account for the six months ended June 30, 2024 is as follows:     Intangible asset   Net book amount at December 31, 2023   $ 3,394,645   Additions     -   Disposal     -   Amortization     (188,591 ) Net book amount at June 30, 2024   $ 3,206,054

v3.24.3

Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Schedule of Leases Certain Assets Under Lease Agreements	The Company’s leases certain assets under lease agreements.     Office     Laboratory                         Equipment     Equipment     Vehicle     Office     Total   Cost                               Balance at December 31, 2023   $ 28,429     $ 94,062     $ 169,115     $ 1,664,637     $ 1,956,243   Additions     -       37,007       -       63,571       100,578   Effects of currency translation     (839 )     (2,958 )     (4,994 )     (49,468 )     (58,259 ) Balance at June 30, 2024   $ 27,590     $ 128,111     $ 164,121     $ 1,678,740     $ 1,998,562                                             Accumulated amortization                                         Balance at December 31, 2023   $ 17,927     $ 37,485     $ 74,724     $ 493,937     $ 624,073   Amortization     5,099       9,912       26,061       119,728       160,800   Effects of currency translation     (554 )     (1,156 )     (2,334 )     (15,167 )     (19,211 ) Balance at June 30, 2024   $ 22,472     $ 46,241     $ 98,451     $ 598,498     $ 765,662   Net book value                                         December 31, 2023   $ 10,502     $ 56,577     $ 94,391     $ 1,170,700     $ 1,332,170   June 30, 2024   $ 5,118     $ 81,870     $ 65,670     $ 1,080,242     $ 1,232,900
Schedule of Future Lease Payments	The Company’s lease liabilities consist of office and laboratory equipment and office space. The present value of future lease payments were measured using an weighted average incremental borrowing rate of 9.80% per annum as of June 30, 2024.     Total   Balance at December 31, 2023   $ 1,454,186   Additions     100,578   Interest expenses(*)     67,876   Lease payments (*)     (214,180 ) Effects of currency translation     (42,724 ) Balance at June 30, 2024   $ 1,365,736   (*) Payment of lease obligation under financing activities is $146,304, excluding interest expense.
Schedule of Lease Liabilities	Lease liabilities   June 30, 2024   Current portion   $ 319,573   Long-term portion     1,046,163   Total lease liabilities   $ 1,365,736

v3.24.3

Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Accounts Payable and Accrued Expenses [Abstarct]
Schedule of Accounts Payable and Accrued Liabilities	June 30,     December 31,       2024     2023   Accounts payable   $ 1,653,002     $ 2,326,439   Accrued expenses     1,130,423       725,208   Payroll liabilities     120,448       132,734       $ 2,903,873     $ 3,184,381

v3.24.3

Convertible Debt – Related Party (Tables)	6 Months Ended
	Jun. 30, 2024
Convertible Debt – Related Party [Abstract]
Schedule of Convertible Debt - Related Party	A continuity of the Company’s Convertible Debt – Related Party is as follows:     2019 and 2020 Convertible Loans   Balance, December 31, 2023   $ 33,118   Effects of currency translation     (978 ) Balance, June 30, 2024   $ 32,140

v3.24.3

Convertible Debt (Tables)	6 Months Ended
	Jun. 30, 2024
Convertible Debt [Abstract]
Schedule of Convertible Loan	A continuity of the Company’s Convertible loan is as follows:     2017 Convertible Loans   Balance, December 31, 2023   $ 44,310   Effects of currency translation     (1,307 ) Balance, June 30, 2024   $ 43,003
Schedule of Changes in the Balance of Convertible Notes	Changes in the balance of the convertible notes are as follows:           Carrying             Amount at       Face Value     Fair value   Balance at December 31, 2023   $ 6,400,000     $ 4,859,000   Issuance of convertible promissory notes     3,300,000       2,970,000   Repayments of convertible promissory notes     (787,633 )     (787,633 ) Conversion of notes with ordinary shares     (1,770,577 )     (1,770,577 ) Change in fair value of convertible promissory notes     -       528,210   Balance at June 30, 2024   $ 7,141,790     $ 5,799,000
Schedule of Significant Inputs into the Fair Value of the Promissory Note	A summary of the Company’s significant inputs into the fair value of the Promissory Notes is as follows:       June 30,         2024   Stock price   $ 0.40 - 0.90   Expected life in years     0.50 - 0.92   Risk free rate     5.25% - 5.56% Expected volatility     105% - 130%

v3.24.3

Silent Partnerships (Tables)	6 Months Ended
	Jun. 30, 2024
Silent Partnerships [Abstract]
Schedule of Continuity of the Company’s Silent Partnerships	A continuity of the Company’s silent partnerships is as follows:     3% SPAs     3.5% SPAs     8.5% SPAs     Total   Balance, December 31, 2023   $ 596,257     $ 48,695     $ 385,214     $ 1,030,166   Accretion     22,367       1,788       6,347       30,502   Effects of currency translation     (17,716 )     (1,447 )     (11,407 )     (30,570 ) Balance, June 30, 2024   $ 600,908     $ 49,036     $ 380,154     $ 1,030,098

v3.24.3

Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Summary of Activity	A summary of activity during the six months ended June 30, 2024 is as follows:     Warrant     Weighted-Average     Weighted-Average       Outstanding     Exercise Price     Life (years)   Balance as of December 31, 2023     6,597,500     $ 1.86       3.39   Grants     -       -       -   Exercised     -       -       -   Expired     -       -       -   Balance as of June 30, 2024     6,597,500     $ 1.86       2.90
Schedule of the Estimated Fair Values of the Stock Options	For the six months ended June 30, 2023, the estimated fair values of the stock options are as follows:       June 30,         2023   Exercise price   $ 4.78 - 7.02   Expected term     5.25 - 7.00 years   Expected average volatility     70% - 76%   Expected dividend yield     -   Risk-free interest rate     3.48% - 4.27%
Schedule of Summary of Activity	A summary of activity during the six months ended June 30, 2024 follows:     Stock options     Weighted-Average     Weighted-Average       Outstanding     Exercise Price     Life (years)   Balance as of December 31, 2023     2,727,150     $ 6.89       8.44   Grants     -       -       -   Exercised     -       -       -   Forfeited/Cancelled     -       -       -   Expiry     -       -       -   Balance as of June 30, 2024     2,727,150     $ 6.89       7.89                             Exercisable as of June 30, 2024     1,958,775     $ 6.48       7.57   Expect to vest     768,375     $ 7.76       2.22   A summary of activity during the six months ended June 30, 2023 follows:     Stock options     Weighted-Average     Weighted-Average       Outstanding     Exercise Price     Life (years)   Balance as of December 31, 2022     2,394,150     $ 7.18       9.11   Grants     312,500       5.06       10.00   Exercised     -       -       -   Forfeited     (27,592 )     6.88       -   Expired     -       -       -   Balance as of June 30, 2023     2,679,058     $ 6.97       8.80                             Exercisable as of June 30, 2023     1,567,950     $ 5.95       8.40

v3.24.3

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Schedule of Remuneration of Directors and Key Management	The remuneration of directors and key management personnel during the six months ended June 30, 2024 and 2023 was as follows:     Six months ended       June 30,       2024     2023   Salaries and benefits   $ 552,926     $ 921,492
Schedule of Remuneration Paid to Related Parties Other than Key Personnel	Remuneration paid to related parties other than key personnel during the six months ended June 30, 2024 and 2023 was as follows:     Six months ended       June 30,       2024     2023   Salaries and benefits   $ 21,292     $ 14,956

v3.24.3

Government Grants (Tables)	6 Months Ended
	Jun. 30, 2024
Government Grants [Abstract]
Schedule of Government Grants Related to Research and Development Activities	The Company receives government grants related to its research and development activities. The amount of government grants received during the six months ended June 30, 2024 and 2023 and recognized in Other Income were as follows:     Six months ended       June 30,   Research and Development Projects   2024     2023   Multi-marker test for the early detection of pancreatic cancer   $ 46,087     $ 28,117

v3.24.3

Financial Instrument Risk Management (Tables)	6 Months Ended
	Jun. 30, 2024
Financial Instrument Risk Management [Abstract]
Schedule of Contractual Maturities of the Company’s Financial Liabilities	The following is an analysis of the contractual maturities of the Company’s financial liabilities as at June 30, 2024 and December 31, 2023:     Within     More than     More than       one year     one year     five years   Accounts payable and accrued liabilities   $ 2,903,873     $ -     $ -   Accounts payable - related party     426,637       -       -   Deferred revenue     116,679       -       -   Convertible promissory note to be settled with ordinary shares     5,799,000       -       -   Convertible loans     75,143       -       -   Loans payable     -       -       -   Silent partnerships     49,036       981,062       -   Lease liabilities     319,573       688,672       357,491   Intellectual property acquisition liability - related party     324,003       551,561       -       $ 10,013,944     $ 2,221,295     $ 357,491       Within     More than     More than       one year     one year     five years   Accounts payable and accrued liabilities   $ 3,184,381     $ -     $ -   Accounts payable and accrued expenses– related party     299,936       -       -   Deferred revenue     138,889       -       -   Convertible promissory note     4,859,000       -       -   Convertible loans     77,428       -       -   Silent partnerships     -       1,030,166       -   Lease liabilities     288,463       812,910       352,813   Intellectual property acquisition liability - related party     388,839       726,977       -       $ 9,236,936     $ 2,570,053     $ 352,813

v3.24.3

Operating Expenses (Tables)	6 Months Ended
	Jun. 30, 2024
Operating Expenses [Abstract]
Schedule of Operating Expenses	For the six months ended June 30, 2024 and 2023, operating expenses consisted of the following:     Six months ended       June 30,   Sales and marketing   2024     2023   Salaries and Benefits   $ 745,716     $ 615,147   Professional and consulting fees     655,810       1,143,077   Office expenses     25,360       -   Travel and entertainment     46,832       57,943   Depreciation and amortization     2,336       -   Marketing and advertising     885,051       2,176,808       $ 2,361,105     $ 3,992,975       Six months ended       June 30,   Research and development   2024     2023   Salaries and benefits   $ 2,055,067     $ 2,028,880   Professional fees     299,044       665,894   Clinical studies     322,000       2,162,000   Office expenses     87,885       193,936   Travel and entertainment     59,123       100,383   Depreciation and amortization     284,591       210,875   Materials for clinical studies     134,912       119,261       $ 3,242,622     $ 5,481,229         Six months ended       June 30,   General and administrative   2024     2023   Salaries and benefits   $ 1,524,397     $ 1,271,181   Employee stock option expense     1,028,383       1,668,673   Professional and consulting fees     1,038,126       1,146,792   Office expenses     411,367       345,752   Insurance     261,473       478,149   Travel and entertainment     48,872       69,924   Depreciation and amortization     210,021       246,710       $ 4,522,639     $ 5,227,181

v3.24.3

Nature of Operations and Going Concern (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Nature of Operations and Going Concern [Abstract]
Accumulated deficit totaling	$ (80,351,783)	$ (69,328,021)
Operating activities	8,100,000
Cash	977,764
Amount of sale of shares and warrants	16,500,000
Net proceeds	$ 3,500,000
Percentage of reduction of personnel	65.00%

v3.24.3

Summary of Significant Accounting Policies and Use of Estimates and Judgments (Details)	6 Months Ended
	Jun. 30, 2024 segments
Summary of Significant Accounting Policies and Use of Estimates and Judgments [Abstract]
Number of operating segment	1

v3.24.3

Summary of Significant Accounting Policies and Use of Estimates and Judgments (Details) - Schedule of Estimated Useful Lives	6 Months Ended
	Jun. 30, 2024
Laboratory equipment [Member] | Bottom of range [member]
Summary of Significant Accounting Policies and Use of Estimates and Judgments (Details) - Schedule of Estimated Useful Lives [Line Items]
Estimated useful lives of the assets	5 years
Laboratory equipment [Member] | Top of range [member]
Summary of Significant Accounting Policies and Use of Estimates and Judgments (Details) - Schedule of Estimated Useful Lives [Line Items]
Estimated useful lives of the assets	10 years
Office equipment [Member] | Bottom of range [member]
Summary of Significant Accounting Policies and Use of Estimates and Judgments (Details) - Schedule of Estimated Useful Lives [Line Items]
Estimated useful lives of the assets	3 years
Office equipment [Member] | Top of range [member]
Summary of Significant Accounting Policies and Use of Estimates and Judgments (Details) - Schedule of Estimated Useful Lives [Line Items]
Estimated useful lives of the assets	10 years

v3.24.3

Trade and Other Receivables (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Trade and Other Receivables (Details) [Line Items]
Trade receivable	$ 10,795
Trade Receivable [Member]
Trade and Other Receivables (Details) [Line Items]
Allowance for doubtful accounts	$ 5,361	$ 17,065

v3.24.3

Trade and Other Receivables (Details) - Schedule of Trade and Other Receivables - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Trade and Other Receivables [Abstract]
Trade receivables	$ 172,047	$ 121,735
Less: allowance for doubtful accounts	(32,633)	(28,180)
Trade receivables, net	$ 139,414	$ 93,555

v3.24.3

Inventories (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Inventories [Abstract]
Inventory write down	$ 67,080

v3.24.3

Inventories (Details) - Schedule of Inventories - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Inventories [Abstract]
Raw materials	$ 373,718	$ 430,004
Finished goods	178,810	240,467
Inventories, Gross	552,528	670,471
Less: Reserve	(31,997)	(56,833)
Inventories, Net	$ 520,531	$ 613,638

v3.24.3

Prepaid and Other Current Assets (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Prepaid and Other Current Assets [Abstract]
Valuation reserve	$ 16,090	$ 53,295

v3.24.3

Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Prepaid and Other Current Assets [Abstract]
Prepaid insurance	$ 220,668	$ 478,116
Other prepaid expense	204,198	327,538
Security deposit	131,073	135,061
VAT receivable	195,950	260,955
Other assets	105	108
Prepaid expenses and other current assets	$ 751,994	$ 1,201,778

v3.24.3

Property and Equipment (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Property and Equipment (Details) [Line Items]
Depreciation	$ 104,024
Depreciation and amortization expense	43,496	$ 0
Property and Equipment [Member]
Property and Equipment (Details) [Line Items]
Depreciation	$ 104,024	$ 112,933

v3.24.3

Property and Equipment (Details) - Schedule of Changes in Property Equipment and Accumulated Depreciation - USD ($)	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Cost
Balance at December 31, 2023	$ 1,973,341
Balance at June 30, 2024	1,991,860
Additions	120,660
Disposal/reclasses	(43,496)
Effects of currency translation	(58,645)
Accumulated depreciation
Balance at December 31, 2023	271,024
Balance at June 30, 2024	366,487
Net book value	1,625,373	$ 1,702,317
Depreciation	104,024
Disposal/reclasses
Effects of currency translation	(8,561)
Laboratory equipment [Member]
Cost
Balance at December 31, 2023	1,494,732
Balance at June 30, 2024	1,478,566
Additions	50,861
Disposal/reclasses	(22,751)
Effects of currency translation	(44,276)
Accumulated depreciation
Balance at December 31, 2023	184,149
Balance at June 30, 2024	249,055
Net book value	1,229,511	1,310,583
Depreciation	70,743
Disposal/reclasses
Effects of currency translation	(5,837)
Office equipment [Member]
Cost
Balance at December 31, 2023	418,680
Balance at June 30, 2024	464,436
Additions	69,799
Disposal/reclasses	(11,399)
Effects of currency translation	(12,644)
Accumulated depreciation
Balance at December 31, 2023	86,875
Balance at June 30, 2024	117,432
Net book value	347,004	331,805
Depreciation	33,281
Disposal/reclasses
Effects of currency translation	(2,724)
Construction in progress [Member]
Cost
Balance at December 31, 2023	59,929
Balance at June 30, 2024	48,858
Additions
Disposal/reclasses	(9,346)
Effects of currency translation	(1,725)
Accumulated depreciation
Balance at December 31, 2023
Balance at June 30, 2024
Net book value	48,858	$ 59,929
Depreciation
Disposal/reclasses
Effects of currency translation

v3.24.3

Intangible Asset (Details) - USD ($)		6 Months Ended		12 Months Ended
	Feb. 15, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Intangible Asset [Line Items]
Cash payment		$ 300,000
Revenue term	10 years
Intangible asset purchase useful life	10 years
Closing value per share (in Dollars per share)	$ 6.85
Present value of the future payments	10.00%
Amortization expenses		188,591
Interest expense		$ 659,473	$ 88,759
Payment discount rate		2.00%
Licensing Agreement [Member]
Intangible Asset [Line Items]
Cash payment	$ 2,000,000
Intellectual Property Asset Purchase Agreement [Member]
Intangible Asset [Line Items]
Interest expense		$ 50,858
Property acquisition liability		$ 875,564		$ 1,115,816
Intellectual Property Asset Purchase Agreement [Member]
Intangible Asset [Line Items]
Ordinary restricted shares (in Shares)	300,000
Revenue per share (in Dollars per share)	$ 1

v3.24.3

Intangible Asset (Details) - Schedule of Intangible Asset Account	6 Months Ended
	Jun. 30, 2024 USD ($)
Schedule of Intangible Asset Account [Abstract]
Net book amount at December 31, 2023	$ 3,394,645
Additions
Disposal
Amortization	(188,591)
Net book amount at June 30, 2024	$ 3,206,054

v3.24.3

Leases (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Future lease payments percentage	9.80%
Payment of lease obligation	$ 146,304	$ 201,480
Average expected life	4 years 6 months

v3.24.3

Leases (Details) - Schedule of Leases Certain Assets Under Lease Agreements	6 Months Ended
	Jun. 30, 2024 USD ($)
Cost
Cost Beginning Balance	$ 1,956,243
Additions	100,578
Effects of currency translation	(58,259)
Cost Ending Balance	1,998,562
Accumulated amortization
Accumulated amortization Beginning Balance	624,073
Amortization	160,800
Effects of currency translation	(19,211)
Accumulated amortization Ending Balance	765,662
Net book value
Net book value Beginning Balance	1,332,170
Net book value Ending Balance	1,232,900
Office Equipment [Member]
Cost
Cost Beginning Balance	28,429
Additions
Effects of currency translation	(839)
Cost Ending Balance	27,590
Accumulated amortization
Accumulated amortization Beginning Balance	17,927
Amortization	5,099
Effects of currency translation	(554)
Accumulated amortization Ending Balance	22,472
Net book value
Net book value Beginning Balance	10,502
Net book value Ending Balance	5,118
Laboratory Equipment [Member]
Cost
Cost Beginning Balance	94,062
Additions	37,007
Effects of currency translation	(2,958)
Cost Ending Balance	128,111
Accumulated amortization
Accumulated amortization Beginning Balance	37,485
Amortization	9,912
Effects of currency translation	(1,156)
Accumulated amortization Ending Balance	46,241
Net book value
Net book value Beginning Balance	56,577
Net book value Ending Balance	81,870
Vehicle [Member]
Cost
Cost Beginning Balance	169,115
Additions
Effects of currency translation	(4,994)
Cost Ending Balance	164,121
Accumulated amortization
Accumulated amortization Beginning Balance	74,724
Amortization	26,061
Effects of currency translation	(2,334)
Accumulated amortization Ending Balance	98,451
Net book value
Net book value Beginning Balance	94,391
Net book value Ending Balance	65,670
Office [Member]
Cost
Cost Beginning Balance	1,664,637
Additions	63,571
Effects of currency translation	(49,468)
Cost Ending Balance	1,678,740
Accumulated amortization
Accumulated amortization Beginning Balance	493,937
Amortization	119,728
Effects of currency translation	(15,167)
Accumulated amortization Ending Balance	598,498
Net book value
Net book value Beginning Balance	1,170,700
Net book value Ending Balance	$ 1,080,242

v3.24.3

Leases (Details) - Schedule of Future Lease Payments	6 Months Ended
	Jun. 30, 2024 USD ($)
Schedule of Future Lease Payments [Abstract]
Balance at beginning	$ 1,454,186
Additions	100,578
Interest expenses	67,876	[1]
Lease payments	(214,180)	[1]
Effects of currency translation	(42,724)
Balance at ending	$ 1,365,736
[1] Payment of lease obligation under financing activities is $146,304, excluding interest expense.

v3.24.3

Leases (Details) - Schedule of Lease Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Lease Liabilities [Abstract]
Current portion	$ 319,573	$ 288,463
Long-term portion	1,046,163	1,165,723
Total lease liabilities	$ 1,365,736	$ 1,454,186

v3.24.3

Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Accounts Payable and Accrued Expenses [Abstract]
Accounts payable	$ 1,653,002	$ 2,326,439
Accrued expenses	1,130,423	725,208
Payroll liabilities	120,448	132,734
Total	$ 2,903,873	$ 3,184,381

v3.24.3

Convertible Debt – Related Party (Details)			6 Months Ended	12 Months Ended
	Dec. 31, 2020 USD ($) € / shares	Dec. 31, 2019 USD ($) € / shares	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Convertible Debt – Related Party [Line Items]
Loan agreements related parties totaling	$ 467,154	$ 467,154				€ 417,133	€ 417,133
Convertible loans bear interest			8.50%	8.50%	8.50%
Maturity date			December 31, 2025	December 31, 2025
Convertible loans payable					€ 30,000
Loans outstanding, percentage	0.50%	0.50%
Ordinary shares per share (in Euro per share) | € / shares	$ 1	$ 1
Convertible Loans [Member]
Convertible Debt – Related Party [Line Items]
Convertible loans bear interest	3.50%	3.50%				3.50%	3.50%
Maturity date	September 30, 2022	September 30, 2022
Debt discounts totaling						€ 13,064	€ 13,064
Loan Agreement [Member]
Convertible Debt – Related Party [Line Items]
Convertible loans payable | $			$ 32,205	$ 33,118

v3.24.3

Convertible Debt – Related Party (Details) - Schedule of Convertible Debt - Related Party - 2019 and 2020 Convertible Loans [Member]	6 Months Ended
	Jun. 30, 2024 USD ($)
Schedule of Convertible Debt [Line Items]
Balance, December 31, 2023	$ 33,118
Effects of currency translation	(978)
Balance, June 30, 2024	$ 32,140

v3.24.3

Convertible Debt (Details)			1 Months Ended		6 Months Ended		12 Months Ended
	Apr. 18, 2024 USD ($)	Jun. 28, 2023 USD ($) shares	Dec. 31, 2023 USD ($)	Nov. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2024 EUR (€) shares	Sep. 26, 2023 USD ($)	Nov. 30, 2017 USD ($)	Nov. 30, 2017 EUR (€)
Convertible Debt [Line Items]
Percentage of common shares outstanding					4.25%
Promissory notes			$ 6,400,000		$ 7,141,790		$ 6,400,000
Percentage of principal amount		92.00%
Principal amount			$ 1,100,000	$ 1,100,000			$ 1,100,000
Net of discount received	$ 2,970,000
Paid legal fee	25,000
Maturity date					1 year
Percentage of interest			8.50%		8.50%		8.50%	8.50%
Percentage of promissory note premium					8.00%
Business days					5 days
Calendar days					30 days
Percentage of volume weighted average price					110.00%
Trading days					8 days
Floor price per share (in Dollars per share) | $ / shares					$ 2
Monthly payment amount					$ 550,000
Percentage of redemption premium					8.00%			8.00%
Percentage of monthly payment					10.00%
Commitment fee					$ 250,000
Ordinary shares (in Shares) | shares		54,428
Original issue discount					440,000
Percentage of premium			8.00%	8.00%
Percentage of default interest			15.00%	15.00%
Principal reductions					2,600,000
Interest of promissory note					600,000
Net proceeds					500,000
Accrued interest					70,782
Change in fair value of convertible notes					528,210	$ (45,000)
Fair value balance amount					$ 5,799,000		$ 4,859,000
Bottom of Range [Member]
Convertible Debt [Line Items]
Consecutive trading days					5 days
Top of Range [Member]
Convertible Debt [Line Items]
Consecutive trading days					7 days
2017 Convertible Loans [Member]
Convertible Debt [Line Items]
Total loans										$ 92,007	€ 80,278
Payable on demand, amount					$ 43,003			€ 40,139
Commitment Amount [Member]
Convertible Debt [Line Items]
Promissory notes		$ 50,000,000
Initial Promissory Note [Member]
Convertible Debt [Line Items]
Promissory notes					4.9986
Principal amount		5,500,000
Net of discount received		$ 5,060,000
Face value					5,500,000
Fair value					$ 5,060,000
Converted ordinary shares (in Shares) | shares					3,366,093
Second Promissory Note [Member]
Convertible Debt [Line Items]
Promissory notes					$ 3.5424
Principal amount					1,770,577				$ 5,500,000
Net of discount received									$ 5,060,000
Fair value					5,008,000
Repaid principal amounts					787,633
Accrued interest					$ 383,980
Second Promissory Note [Member] | Bottom of Range [Member]
Convertible Debt [Line Items]
Conversion prices (in Dollars per share) | $ / shares					$ 0.18
Second Promissory Note [Member] | Top of Range [Member]
Convertible Debt [Line Items]
Conversion prices (in Dollars per share) | $ / shares					$ 0.95
Third Promissory Note [Member]
Convertible Debt [Line Items]
Principal amount	$ 3,300,000
Fair value					$ 2,822,000
Promissory Notes [Member]
Convertible Debt [Line Items]
Percentage of interest				15.00%	15.00%			15.00%
Calendar days					30 days
Trading days					3 days
Consecutive trading days					7 days
Percentage of redemption premium					8.00%			8.00%
Percentage of all outstanding					50.00%
Ordinary shares issued (in Shares) | shares					4,421,093			4,421,093
VWAPs [Member]
Convertible Debt [Line Items]
Percentage of volume weighted average price					92.00%

v3.24.3

Convertible Debt (Details) - Schedule of Convertible Loan - 2017 Convertible Loans [Member]	6 Months Ended
	Jun. 30, 2024 USD ($)
Schedule of Convertible Loan [Line Items]
Balance, beginning	$ 44,310
Effects of currency translation	(1,307)
Balance, ending	$ 43,003

v3.24.3

Convertible Debt (Details) - Schedule of Changes in the Balance of Convertible Notes	6 Months Ended
	Jun. 30, 2024 USD ($)
Schedule of Changes in the Balance of Convertible Notes [Abstract]
Balance at beginning, Face Value	$ 6,400,000
Balance at beginning, Carrying Amount at Fair Value	4,859,000
Issuance of convertible promissory notes, Face Value	3,300,000
Issuance of convertible promissory notes, Carrying Amount at Fair Value	2,970,000
Repayments of convertible promissory notes, Face Value	(787,633)
Repayments of convertible promissory notes, Carrying Amount at Fair Value	(787,633)
Conversion of notes with ordinary shares, Face Value	(1,770,577)
Conversion of notes with ordinary shares, Carrying Amount at Fair Value	(1,770,577)
Change in fair value of convertible promissory notes, Face Value
Change in fair value of convertible promissory notes, Carrying Amount at Fair Value	528,210
Balance at ending, Face Value	7,141,790
Balance at ending, Carrying Amount at Fair Value	$ 5,799,000

v3.24.3

Convertible Debt (Details) - Schedule of Significant Inputs into the Fair Value of the Promissory Note	6 Months Ended
	Jun. 30, 2024
Bottom of range [Member] | Stock price [member]
Schedule of Promissory Notes [Line Items]
Significant inputs	$0.40
Bottom of range [Member] | Expected life in years [member]
Schedule of Promissory Notes [Line Items]
Significant inputs	0.50
Bottom of range [Member] | Risk free rate [member]
Schedule of Promissory Notes [Line Items]
Significant inputs	5.25%
Bottom of range [Member] | Expected volatility [member]
Schedule of Promissory Notes [Line Items]
Significant inputs	105%
Top of range [Member] | Stock price [member]
Schedule of Promissory Notes [Line Items]
Significant inputs	0.90
Top of range [Member] | Expected life in years [member]
Schedule of Promissory Notes [Line Items]
Significant inputs	0.92
Top of range [Member] | Risk free rate [member]
Schedule of Promissory Notes [Line Items]
Significant inputs	5.56%
Top of range [Member] | Expected volatility [member]
Schedule of Promissory Notes [Line Items]
Significant inputs	130%

v3.24.3

Silent Partnerships (Details) - Schedule of Continuity of the Company’s Silent Partnerships	6 Months Ended
	Jun. 30, 2024 USD ($)
Schedule of Continuity of the Company’s Silent Partnerships [Line Items]
Balance, December 31, 2023	$ 1,030,166
Accretion	30,502
Effects of currency translation	(30,570)
Balance, June 30, 2024	1,030,098
3% SPAs [Member]
Schedule of Continuity of the Company’s Silent Partnerships [Line Items]
Balance, December 31, 2023	596,257
Accretion	22,367
Effects of currency translation	(17,716)
Balance, June 30, 2024	600,908
3.5% SPAs [Member]
Schedule of Continuity of the Company’s Silent Partnerships [Line Items]
Balance, December 31, 2023	48,695
Accretion	1,788
Effects of currency translation	(1,447)
Balance, June 30, 2024	49,036
8.5% SPAs [Member]
Schedule of Continuity of the Company’s Silent Partnerships [Line Items]
Balance, December 31, 2023	385,214
Accretion	6,347
Effects of currency translation	(11,407)
Balance, June 30, 2024	$ 380,154

v3.24.3

Equity (Details)		6 Months Ended		12 Months Ended
	Nov. 13, 2023 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($) shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 shares	Dec. 31, 2021 USD ($) $ / shares shares	Jun. 30, 2024 € / shares	May 31, 2024 shares	Feb. 15, 2023 $ / shares
Equity [Line Items]
Ordinary shares authorized				45,000,000
Ordinary shares outstanding								90,000,000
Vote per share		one
Price per share | $ / shares									$ 6.85
Ordinary share issued		1,055,000
Ordinary restricted shares		3,366,093
Conversion of debt (in Dollars) | $		$ 2,154,557
Ordinary shares at market prices					3.00%
Net proceeds (in Dollars) | $		3,500,000
Ordinary shares issued for services (in Dollars) | $		177,690
Convertible promissory note (in Dollars) | $		250,000
Intangible assets (in Dollars) | $		2,055,000
Assigned value (in Dollars) | $	$ 0
Intrinsic value of the warrants (in Dollars) | $		0
Stock options			312,500
Stock options value (in Dollars) | $			$ 1,072,612
Share-based compensation (in Dollars) | $		1,028,383	$ 1,668,673
Intrinsic value of the stock options (in Dollars) | $		$ 0
Intangible assets other than goodwill [Member]
Equity [Line Items]
Ordinary shares issued		300,000
Stock Option [Member]
Equity [Line Items]
Ordinary shares issued				875,000	500,000	2,300,000
Warrant [Member]
Equity [Line Items]
Price per share | $ / shares	$ 1.2
Ordinary shares issued	4,166,667	305,771				3,755,000
Underwriting warrants						161,000
Underwriting warrants amount (in Dollars) | $						$ 754,286
Exercise or strike price (in Dollars per share) | $ / shares						$ 3
Dividend rate						0.00%
Warrant [Member] | Bottom of range [Member]
Equity [Line Items]
Expiration term						2 years
Risk-free interest rate						0.16%
Stock price at time of issuance (in Dollars per share) | $ / shares						$ 0.283
Volatility						75.00%
Warrant [Member] | Top of range [Member]
Equity [Line Items]
Expiration term						5 years
Risk-free interest rate						1.08%
Stock price at time of issuance (in Dollars per share) | $ / shares						$ 1.602
Volatility						95.00%
Loan commitments [Member]
Equity [Line Items]
Ordinary shares issued		54,428
Ordinary shares [Member]
Equity [Line Items]
Ordinary shares authorized								90,000,000
Ordinary shares outstanding								225,000,000
Gross proceeds (in Dollars) | $		$ 515,262
Issued capital [Member]
Equity [Line Items]
Ordinary shares outstanding		25,586,575	15,631,521	21,165,482	14,629,457
Price per share | € / shares							€ 0.01
Controlled Equity Offering [Member]
Equity [Line Items]
Price per share | $ / shares				$ 6.16
Ordinary shares issued				307,365
Net proceeds (in Dollars) | $				$ 1,893,196
November 2023 Financing [Member]
Equity [Line Items]
Ordinary share issued		34,500

v3.24.3

Equity (Details) - Schedule of Summary of Activity - Warrant [Member]		6 Months Ended
	Dec. 31, 2023 $ / shares	Jun. 30, 2024 $ / shares
Schedule of Summary of Activity [Line Items]
Warrant Outstanding, Balance	6,597,500	6,597,500
Weighted-Average Exercise Price, Balance	$ 1.86	$ 1.86
Weighted-Average Life (years), Balance	3 years 4 months 20 days	2 years 10 months 24 days
Warrant Outstanding, Grants
Weighted-Average Exercise Price, Grants
Weighted-Average Life (years), Grants
Warrant Outstanding, Exercised
Weighted-Average Exercise Price, Exercised
Weighted-Average Life (years), Exercised
Warrant Outstanding, Expired
Weighted-Average Exercise Price, Expired
Weighted-Average Life (years), Expired

v3.24.3

Equity (Details) - Schedule of the Estimated Fair Values of the Stock Options - Stock Option [Member]	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares
Schedule of the Estimated Fair Values of the Stock Options [Line Items]
Expected dividend yield (in Dollars) | $
Bottom of Range [Member]
Schedule of the Estimated Fair Values of the Stock Options [Line Items]
Exercise price (in Dollars per share)	$ 4.78
Expected term	5 years 3 months
Expected average volatility	70.00%
Risk-free interest rate	3.48%
Top of range [Member]
Schedule of the Estimated Fair Values of the Stock Options [Line Items]
Exercise price (in Dollars per share)	$ 7.02
Expected term	7 years
Expected average volatility	76.00%
Risk-free interest rate	4.27%

v3.24.3

Equity (Details) - Schedule of Summary of Activity - Stock Options [Member]			6 Months Ended
	Dec. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares	Jun. 30, 2024 $ / shares	Jun. 30, 2023 $ / shares
Schedule of Summary of Activity [Line Items]
Stock options Outstanding, balance ending	2,727,150	2,394,150	2,727,150	2,679,058
Weighted-Average Exercise Price, balance ending	$ 6.89	$ 7.18	$ 6.89	$ 6.97
Weighted- Average Life (years), balance ending	8 years 5 months 8 days	9 years 1 month 9 days
Stock options Outstanding, Grants				312,500
Weighted-Average Exercise Price, Grants				$ 5.06
Weighted-Average Life (years), Grants				10 years
Stock options Outstanding, Exercised
Weighted-Average Exercise Price, Exercised
Weighted-Average Life (years), Exercised
Stock options Outstanding, Forfeited/Cancelled				(27,592)
Weighted-Average Exercise Price, Forfeited/Cancelled				$ 6.88
Weighted-Average Life (years), Forfeited/Cancelled
Stock options Outstanding, Expiry
Weighted-Average Exercise Price, Expiry
Weighted-Average Life (years), Expiry
Weighted-Average Life (years), balance ending			7 years 10 months 20 days	8 years 9 months 18 days
Stock options Outstanding, Exercisable			1,958,775	1,567,950
Weighted-Average Exercise Price, Exercisable			$ 6.48	$ 5.95
Weighted-Average Life (years), Exercisable			7 years 6 months 25 days	8 years 4 months 24 days
Stock options Outstanding, Expected to Vest			768,375
Weighted-Average Exercise Price, Expected to Vest			$ 7.76
Weighted-Average Life (years), Expected to Vest			2 years 2 months 19 days

v3.24.3

Related Party Transactions (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2024 EUR (€)	Dec. 31, 2023 EUR (€)
Related Party Transactions [Line Items]
Accounts payable, related party	$ 426,637		$ 299,936
Accrued management salaries	358,398		267,234
Expenses for cost of royalties and other associated cost	186,601	$ 52,264
Loan amount	214,264		220,784	€ 200,000	€ 200,000
Carrying value	$ 267,206		$ 271,354
Interest rate	8.50%		8.50%	8.50%	8.50%
Loan due amount			$ 200,000	€ 200,000
Maturity date	December 31, 2025		December 31, 2025
Incurred interest expense	$ 9,716	16,664
Accretion expense	3,884	6,807
Related Party [Member]
Related Party Transactions [Line Items]
Accounts payable, related party	37,088		$ 32,702
ColoAlert AS [Member]
Related Party Transactions [Line Items]
Amount paid	155,450	$ 173,844
Unpaid costs	$ 31,151		$ 0

v3.24.3

Related Party Transactions (Details) - Schedule of Remuneration of Directors and Key Management - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Remuneration of Directors and Key Management [Abstract]
Salaries and benefits	$ 552,926	$ 921,492

v3.24.3

Related Party Transactions (Details) - Schedule of Remuneration Paid to Related Parties Other than Key Personnel - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Remuneration Paid to Related Parties Other than Key Personnel [Abstract]
Salaries and benefits	$ 21,292	$ 14,956

v3.24.3

Government Grants (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Government Grants [Abstract]
Remaining grant balances	$ 46,010	$ 6,604

v3.24.3

Government Grants (Details) - Schedule of Government Grants Related to Research and Development Activities - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Government Grants Related to Research and Development Activities [Abstract]
Multi-marker test for the early detection of pancreatic cancer	$ 46,087	$ 28,117

v3.24.3

Financial Instrument Risk Management (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Financial Instrument Risk Management [Line Items]
Bad debt expense	$ 16,090	$ 53,295
Unrestricted cash	977,764	7,070,925
Current liabilities	$ 5,799,000	$ 4,859,000
Foreign exchange risk, description	As the Company operates in Germany it holds a portion of its cash balances in Euro to approximate between three to twelve months estimated operating needs. The remainder of the Company’s cash is held in U.S. Dollars, the Company’s reporting currency, which is also the currency of the Company’s largest cash outlays over the next twenty-four months.

v3.24.3

Financial Instrument Risk Management (Details) - Schedule of Contractual Maturities of the Company’s Financial Liabilities - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Within one year [Member]
Financial Instrument Risk Management (Details) - Schedule of Contractual Maturities of the Company’s Financial Liabilities [Line Items]
Accounts payable and accrued liabilities	$ 2,903,873	$ 3,184,381
Accounts payable - related party	426,637	299,936
Deferred revenue	116,679	138,889
Convertible promissory note to be settled with ordinary shares	5,799,000	4,859,000
Convertible loans	75,143	77,428
Loans payable
Silent partnerships	49,036
Lease liabilities	319,573	288,463
Intellectual property acquisition liability - related party	324,003	388,839
Total	10,013,944	9,236,936
More than one year [Member]
Financial Instrument Risk Management (Details) - Schedule of Contractual Maturities of the Company’s Financial Liabilities [Line Items]
Accounts payable and accrued liabilities
Accounts payable - related party
Deferred revenue
Convertible promissory note to be settled with ordinary shares
Convertible loans
Loans payable
Silent partnerships	981,062	1,030,166
Lease liabilities	688,672	812,910
Intellectual property acquisition liability - related party	551,561	726,977
Total	2,221,295	2,570,053
More than five years [Member]
Financial Instrument Risk Management (Details) - Schedule of Contractual Maturities of the Company’s Financial Liabilities [Line Items]
Accounts payable and accrued liabilities
Accounts payable - related party
Deferred revenue
Convertible promissory note to be settled with ordinary shares
Convertible loans
Loans payable
Silent partnerships
Lease liabilities	357,491	352,813
Intellectual property acquisition liability - related party
Total	$ 357,491	$ 352,813

v3.24.3

Concentrations (Details)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
One Customer [Member]
Concentrations (Details) [Line Items]
Revenue percentage	43.00%	18.00%

v3.24.3

Operating Expenses (Details) - Schedule of Operating Expenses - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Operating Expenses [Line Items]
Depreciation and amortization	$ 160,800
Total of General and administrative	4,522,639	$ 5,227,181
Total of Research and development	3,242,622	5,481,229
Total of Sales and marketing	2,361,105	3,992,975
Sales and marketing [Member]
Schedule of Operating Expenses [Line Items]
Salaries and benefits	745,716	615,147
Professional and consulting fees	655,810	1,143,077
Office expenses	25,360
Travel and entertainment	46,832	57,943
Depreciation and amortization	2,336
Marketing and advertising	885,051	2,176,808
Research and development [Member]
Schedule of Operating Expenses [Line Items]
Salaries and benefits	2,055,067	2,028,880
Professional and consulting fees	299,044	665,894
Clinical studies	322,000	2,162,000
Office expenses	87,885	193,936
Travel and entertainment	59,123	100,383
Depreciation and amortization	284,591	210,875
Materials for clinical studies	134,912	119,261
General and administrative [Member]
Schedule of Operating Expenses [Line Items]
Salaries and benefits	1,524,397	1,271,181
Employee stock option expense	1,028,383	1,668,673
Professional and consulting fees	1,038,126	1,146,792
Office expenses	411,367	345,752
Insurance	261,473	478,149
Travel and entertainment	48,872	69,924
Depreciation and amortization	$ 210,021	$ 246,710

v3.24.3

Subsequent Events (Details)		1 Months Ended		6 Months Ended
	Oct. 08, 2024 USD ($) $ / shares	Oct. 31, 2024 EUR (€)	Jul. 31, 2024 EUR (€)	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($)
Subsequent Events [Line Items]
Received proceeds (in Dollars)				$ 515,262	$ 1,894,742
Principal redeuction of convertible notes (in Dollars)				$ 5,284,550
Percentage of reduction of personnel				65.00%
Trading Days				8 days
Receivable [Member]
Subsequent Events [Line Items]
Received proceeds (in Dollars)				$ 3,787,312
Subsequent Events After Reporting Period [Member]
Subsequent Events [Line Items]
Percentage of reduction of personnel		65.00%	65.00%
Payments from sale of EQL business (in Euro) | €		€ 35,000	€ 35,000
Original issue discount rate	10.00%
Interest rate per annum	7.00%
Increase of default interest rate	15.00%
Percentage of note premium advance	5.00%
Fixed conversion price per share (in Dollars per share) | $ / shares	$ 0.25
Percentage of average volume weighted average prices	92.00%
Trading Days	8 days
Subsequent Events After Reporting Period [Member] | CEO [Member]
Subsequent Events [Line Items]
Percentage of original salaries		60.00%	60.00%
Subsequent Events After Reporting Period [Member] | CFO [Member]
Subsequent Events [Line Items]
Percentage of original salaries		50.00%	50.00%
Subsequent Events After Reporting Period [Member] | Consultant [Member]
Subsequent Events [Line Items]
Issued ordinary shares (in Shares) | shares				1,200,000
Subsequent Events After Reporting Period [Member] | Fourth Promissory Note [Member]
Subsequent Events [Line Items]
Original principal amount (in Dollars)	$ 1,500,000
Ordinary shares [member]
Subsequent Events [Line Items]
Ordinary share issued (in Shares) | shares				31,353,911

---